Introduction {#s1}
============

As obligate parasites, viruses must harness host cellular pathways to complete many different steps in viral replication. For example, a large number of enveloped viruses, including HIV-1, usurp the cellular ESCRT ([E]{.ul}ndosomal [S]{.ul}orting [C]{.ul}omplexes [R]{.ul}equired for [T]{.ul}ransport) pathway to bud from cells (for recent reviews, see [@bib33]; [@bib51]; [@bib56]). Viral structural proteins typically use one or more short peptide motifs, termed 'late assembly domains', to bind and recruit early-acting ESCRT factors or ESCRT-associated E3 ubiquitin ligases to sites of viral assembly and budding. The three best characterized viral late assembly domains are: (1) the 'PTAP' motif (Pro-Thr/Ser-Ala-Pro), which binds the UEV domain of the TSG101 subunit of the ESCRT-I complex, (2) the 'YPX~n~L' motif (Tyr-Pro-X~n~-Leu, where X can vary in identity and sequence length), which binds the V domain of the ESCRT factor ALIX, and (3) the 'PPXY' motif (Pro-Pro-X-Tyr), which binds the WW domains of NEDD4 family E3 ubiquitin ligases. All three of these viral late assembly domains mimic cellular protein--protein interactions that facilitate ESCRT-dependent vesiculation processes such as multi-vesicular body (MVB) biogenesis and ectosome formation.

In addition to the three well-characterized late assembly domains described above, there are indications that enveloped viruses can also connect to the ESCRT pathway via alternative interactions that are not yet well-understood. For example, efficient release of the model paramyxovirus, PIV5, requires a non-canonical 'FPIV' late assembly domain motif, ubiquitylation of the matrix (M) protein, and host Angiomotin-like protein 1 (AMOTL1) ([@bib42]; [@bib40]; [@bib19]). There is no evidence that AMOTL1 can bind the FPIV late assembly domain, however, and any relationships between ubiquitin, AMOTL1 and the FPIV late assembly domain activity are not yet understood ([@bib40]).

Owing to its medical importance, HIV-1 has become a leading model for understanding ESCRT pathway recruitment and viral budding. The C-terminal p6 region of the viral Gag structural protein contains canonical PTAP and YPX~n~L motifs that serve as the major functional late assembly domains in most cell types. Nevertheless, the release of 'crippled' HIV-1 Gag constructs that lack both of these late domains can still be stimulated by overexpression of the HECT E3 ubiquitin ligase, NEDD4L (also known as NEDD4-2) ([@bib8]; [@bib50]). Humans express nine different NEDD4 protein family members (reviewed in [@bib22]; [@bib2]), but NEDD4L stimulates virus budding more potently than any other NEDD4 family member, implying that HIV-1 Gag preferentially engages this E3 ubiquitin ligase ([@bib8]; [@bib50]).

Previous studies have defined many of the requirements for NEDD4L-stimulated HIV-1 release. NEDD4L has many different isoforms ([@bib7]; [@bib11]; [@bib23]), but isoform 2 (also called NEDD4-2s, and here termed NEDD4L) potently stimulates the budding of crippled HIV-1 constructs, and uniquely rescues the Gag processing defects that accompany defective budding ([@bib8]; [@bib50]). This NEDD4L isoform contains only the final 31 residues of the N-terminal C2 membrane binding domain, a central linker region that contains four WW domains, and a C-terminal HECT E3 ubiquitin ligase domain that forms Lys-63-linked poly-ubiquitin chains (see [Figure 1A](#fig1){ref-type="fig"}) ([@bib26]; [@bib55]). Stimulation of HIV-1 budding requires NEDD4L E3 ubiquitin ligase activity, indicating that Lys-63-linked poly-ubiquitin chains perform an essential function ([@bib8]; [@bib50]). The functional target(s) of Lys-63 poly-ubiquitylation has not been established definitively, but HIV-1 Gag itself is the leading candidate because functional virus budding correlates with Lys-63-linked poly-ubiquitylation of Gag, and because NEDD4L truncation constructs that include the HECT domain can be functionally rescued by fusion to the HIV-1 Gag-targeting cyclophilin A domain ([@bib55]; [@bib43]). HIV-1 Gag lacks identifiable PPXY motifs, however, and there is no evidence that Gag can bind NEDD4L directly.10.7554/eLife.03778.003Figure 1.AMOT p130 is a NEDD4L binding partner.(**A**) Schematic illustrations of the domain structures and motifs in NEDD4L, AMOT p130 and p80, AMOTL1, AMOTL2 and HIV-1 Gag. Here and throughout, NEDD4L refers to a naturally occurring protein isoform (isoform 2) that contains only the C-terminal 32 residues of the C2 domain (Genebank accession number AAM46201.1, denoted NEDD4Ls in other publications and NEDD4L~ΔC2~ in our previous publication ([@bib8])). To maintain consistency with that publication, the NEDD4L numbering scheme used here corresponds to NEDD4L isoform 1, which is 121 residues longer at the N-terminus and contains the entire C2 domain (denoted NEDD4L~WT~ in reference [@bib8]). (**B**) Affinity co-purification and identification of AMOT p130 as a binding partner of OSF (One-STrEP-FLAG)-tagged NEDD4L. SDS-PAGE/Coomassie-stained gel showing STrEP-Tactin matrix affinity purified proteins from 293T cells transfected with an OSF-NEDD4L expression construct (lane 2) or an empty vector control (lane 1). Labels denote OSF-NEDD4L (bait) and AMOT p130 (prey). Trypsin-digested AMOT p130 peptides identified by mass spectrometric analyses are summarized in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. A representative image from three independent repetitions is shown. (**C**) NEDD4L WW domains are required for AMOT p130 binding. Western blots showing co-immunoprecipitations of endogenous 293T cell AMOT proteins (prey) with OSF-NEDD4L (bait). Panel 1: endogenous AMOT proteins (anti-AMOT blot) co-immunoprecipitated with OSF-NEDD4L baits from cells that lacked exogenous OSF-NEDD4L (lane 1, control), expressed wild type OSF-NEDD4L (lane 2), expressed OSF-NEDD4L~ΔWW~ (lane 3, construct has inactivating point mutations in all four WW domains), expressed OSF-NEDD4L~C942A~ (lane 4, construct has an inactivating point mutation in the HECT E3 domain), or expressed OSF-NEDD4L~C942A/ΔWW~ (lane 5, construct has inactivating point mutations in the WW and HECT E3 domains). Panel 2: same co-immunoprecipitation experiment blotted with anti-FLAG antibodies to detect OSF-NEDD4L proteins. Panel 3: input levels of endogenous AMOT (anti-AMOT blot, 10% of total). Panel 4: input levels of exogenous OSF-NEDD4L (anti-FLAG, 10% of total). Note that endogenous AMOT p80 was present in the input lysate, but did not co-immunoprecipitate with OSF-NEDD4L. Representative image from three independent repetitions.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.003](10.7554/eLife.03778.003)10.7554/eLife.03778.004Figure 1---figure supplement 1.Identification of AMOT p130 as a NEDD4L binding partner.The protein band denoted 'AMOT p130' in [Figure 1B](#fig1){ref-type="fig"}, lane 2 was excised, digested with trypsin and the eluted peptides were identified by mass spectrometry as described in 'Materials and methods'. This analysis was performed three times and the identified peptides are mapped onto the AMOT p130 primary sequence, with peptides identified in experiments 1--3 color coded in black, blue and red, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.004](10.7554/eLife.03778.004)10.7554/eLife.03778.005Figure 1---figure supplement 2.The AMOT p130 PPXY motifs contribute to NEDD4L binding.Western blots show co-immunoprecipitations of OSF-NEDD4L (bait, captured on STrEP-Tactin affinity matrices) with endogenous 293T cells AMOT and exogenously expressed HA-AMOT p130 proteins (prey). Co-immunoprecipitations with OSF-NEDD4L were from cells that lacked exogenous AMOT p130 (lane 1), expressed wild type HA-AMOT p130 (lane 2) or expressed a mutant HA-AMOT p130 protein carrying PP/AA mutations in the three N-terminal 'PPXY' motifs ([@bib52]; [@bib58]). Panel 1: AMOT protein co-immunoprecipitations (anti-AMOT blot) with OSF-NEDD4L. Note that OSF-NEDD4L co-immunoprecipitated low levels of endogenous AMOT p130 (lanes 1 and 3, denoted p130) but not endogenous AMOT p80 (denoted p80 with a dashed line). Panel 2: The same co-immunoprecipitation experiment blotted with anti-HA antibodies to detect exogenously expressed HA-AMOT p130 proteins. Panel 3: The same co-immunoprecipitation experiment blotted with anti-FLAG antibodies to detect exogenously expressed OSF-NEDD4L. Panels 4--6 show the input quantities (10%) of endogenous AMOT and HA-AMOT p130 (panel 4, anti-AMOT), exogenous HA-AMOT p130 (panel 5, anti-HA), and exogenous OSF-NEDD4L (panel 6, anti-FLAG). A representative image from three independent repetitions is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.005](10.7554/eLife.03778.005)

These observations imply that NEDD4L may be recruited to sites of HIV-1 assembly through an alternative mechanism. We undertook the present study with the goal of identifying co-factors that might help link NEDD4L to HIV-1 Gag and stimulate virus budding. We identified Angiomotin (AMOT) as a protein that binds both NEDD4L and HIV-1 Gag, and functions in HIV-1 assembly and release. AMOT is required to complete virion assembly and envelopment, and is therefore a new host factor that acts in a previously uncharacterized step of HIV-1 morphogenesis.

Results {#s2}
=======

NEDD4L binds Angiomotin {#s2-1}
-----------------------

Affinity purification/mass spectrometry experiments were performed to identify candidate NEDD4L binding partners. A number of cellular proteins co-purified with OSF (One-STrEP-FLAG)-tagged NEDD4L, as visualized by SDS-PAGE ([Figure 1B](#fig1){ref-type="fig"}, compare lanes 1 and 2). Prominent co-purifying proteins were excised from the gel, digested with trypsin, and identified by mass spectrometry. The p130 isoform of human Angiomotin was unambiguously identified as a protein that co-purified with OSF-NEDD4L in three independent repetitions of this experiment, (lane 2, labeled AMOT p130, peptide coverage data are summarized in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Smaller AMOT p130 fragments were also identified, as was the related AMOT family protein, Angiomotin-like protein 1 (AMOTL1, data not shown).

Cells express two AMOT isoforms, a longer p130 isoform, and a shorter C-terminal p80 isoform that is expressed from an alternatively spliced message ([Figure 1A](#fig1){ref-type="fig"}) ([@bib36]). AMOT p130 binds NEDD4 protein family members via interactions between the four central NEDD4 WW domains and three PPXY motifs located within the N-terminal extension that is unique to the AMOT p130 isoform ([Figure 1A](#fig1){ref-type="fig"}) ([@bib52]). In good agreement with this report and with our affinity purification/mass spectrometry results, we found that AMOT p130 co-immunoprecipitated with exogenously expressed OSF-NEDD4L ([Figure 1C](#fig1){ref-type="fig"}, panel 1, lane 2). In contrast, AMOT p130 did not co-immunoprecipitate with a mutant OSF-NEDD4L protein that contained inactivating Trp to Ala substitutions in the key PPXY-binding 'W39' residues from each of the four WW domains (denoted OSF-NEDD4L~ΔWW~, panel 1, compare lanes 2 and 3) ([@bib38]).

A previous study has demonstrated that NEDD4 proteins can ubiquitylate and reduce AMOT p130 levels ([@bib52]), and we also observed that OSF-NEDD4L overexpression modestly reduced AMOT p130 levels ([Figure 1C](#fig1){ref-type="fig"}, panel 3, compare lanes 1 and 2). We therefore tested whether AMOT p130 also co-precipitated with OSF-NEDD4L proteins that carried inactivating Cys942Ala point mutations in the active site cysteine of the HECT E3 ubiquitin ligase domain (OSF-NEDD4L~C942A~). This mutation increased OSF-NEDD4L levels in the lysate and immunoprecipitate (panels 2 and 4 compare lanes 4 and 5 to lanes 2 and 3) and restored normal AMOT protein levels (panel 3, compare lanes 4, 5 and 1 to lane 2). Once again, AMOT p130 (and breakdown products) co-immunoprecipitated with OSF-NEDD4L~C942A~ (panel 1, lane 4), but not with a protein that also contained inactivating WW domain mutations (OSF-NEDD4L~ΔWW/C942A~ panel 1, lane 5). AMOT p130 co-precipitation levels were higher with OSF-NEDD4L~C942A~ than with wild type OSF-NEDD4L, presumably owing to the higher cellular levels of both OSF-NEDD4L and AMOT p130 (compare lanes 2 and 4).

Three additional observations confirmed that the NEDD4L WW domains and AMOT p130 PPXY motifs are critical for the NEDD4L-AMOT p130 interaction. Firstly, mutating the three N-terminal AMOT p130 PPXY motifs strongly inhibited co-immunoprecipitation of HA-AMOT p130 with OSF-NEDD4L ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, panel 1, compare lanes 2 and 3). Secondly, endogenous AMOT p80, which lacks the N-terminal PPXY motifs, failed to co-immunoprecipitate with either OSF-NEDD4L or OSF-NEDD4L~C942A~ ([Figure 1C](#fig1){ref-type="fig"}, panel 1, lanes 2 and 4), even though AMOT p80 was present in the 293T cell extracts (panel 3, lanes 1--5). Thirdly, we observed that exogenously expressed, epitope-tagged NEDD4L and AMOT p130 co-localized well in HeLa-M cells, and this co-localization required both the AMOT PPXY and NEDD4L WW motifs (data not shown), in good agreement with previous reports that motins co-localize with other NEDD4 family members ([@bib45]; [@bib52]). Taken together, these experiments demonstrate that NEDD4L interacts specifically with AMOT p130 in cells and that the interaction requires the WW domains of NEDD4L and the PPXY motifs of AMOT.

AMOT binds directly to NEDD4L and to HIV-1 Gag {#s2-2}
----------------------------------------------

Pull-down experiments with purified recombinant proteins were performed to test whether AMOT p130 binds NEDD4L directly, and whether AMOT p130 can also bind HIV-1 Gag and thereby link NEDD4L to the viral Gag protein. Wild type and mutant NEDD4L proteins and an HIV-1 Gag protein that lacked the flexible p6 domain (Gag~Δp6~) were expressed in *Escherichia coli* and purified to near homogeneity ([Figure 2A](#fig2){ref-type="fig"}, lanes 1 and 2, and [Figure 2B](#fig2){ref-type="fig"}, lane 1, respectively). OSF-AMOT p130 was overexpressed in SF-9 insect cells and substantially enriched by binding to STrEP-Tactin affinity resin ([Figure 2A](#fig2){ref-type="fig"}, lane 6 and [Figure 2B](#fig2){ref-type="fig"}, lane 7), although we were unable to purify the protein to homogeneity. As shown in [Figure 2A](#fig2){ref-type="fig"}, NEDD4L did not bind an immobilized control OSF-GFP protein, but bound with at least 1:1 stoichiometry to immobilized OSF-AMOT p130 (compare lanes 4 and 7). In contrast, binding of the NEDD4L~ΔWW~ mutant protein was nearly undetectable ([Figure 2A](#fig2){ref-type="fig"}, compare lanes 7 and 8, particularly in the western blot in panel 2). These experiments confirm that NEDD4L and AMOT p130 bind one another directly, with the WW domains of NEDD4L binding the PPXY motifs of AMOT p130.10.7554/eLife.03778.006Figure 2.AMOT p130 binds directly and specifically to NEDD4L and HIV-1 Gag~∆p6~.(**A**) OSF-AMOT p130 binds NEDD4L. Recombinant OSF-GFP (specificity control, lanes 3--5) or OSF-AMOT p130 (lanes 6--8) were expressed, captured on STrEP-Tactin affinity matrices, and incubated with either a buffer control (lanes 3 and 6) or buffers containing 0.5 µM wild type NEDD4L (lanes 4 and 7) or NEDD4L~ΔWW~ (lanes 5 and 8, inactivating point mutations in all four WW domains). Matrix-bound proteins were released by boiling in denaturing buffer and detected by SDS-PAGE with Coomassie blue staining (panel 1) or by western blotting (panel 2, anti-NEDD4L) to confirm the identities of the bound NEDD4L and help to distinguish background proteins from low-level binding in panel 1. Input levels of NEDD4L (lane 1, 1.5% of total) and NEDD4L~ΔWW~ (lane 2, 1.5% of total) are shown for reference. A representative image from three independent repetitions is shown. (**B**) OSF-AMOT p130 binds HIV-1 Gag~∆p6~. Recombinant OSF-GFP (control, lanes 3--6) or OSF-AMOT p130 (lanes 7--10) were expressed, captured on STrEP-Tactin affinity matrices and incubated with a buffer control (lanes 3 and 7) or with buffers containing 1.0 µM HIV-1 Gag~∆p6~ (lanes 3 and 8), 0.5 µM wild type NEDD4L (lanes 5 and 9) or both proteins (lanes 6 and 10). Matrix-bound proteins were released by boiling in denaturing buffer and detected by SDS-PAGE with Coomassie blue staining (panel 1) or by western blotting to confirm the identities of the bound Gag (panel 2, anti-MA and anti-CA) and NEDD4L (panel 3, anti-NEDD4L) proteins and help to distinguish background proteins from low-level binding in panel 1. Input Gag~∆p6~ (lane 1, 2% of total) and NEDD4L (lane 2, 1.5% of total) are shown for reference. A representative image from three independent repetitions is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.006](10.7554/eLife.03778.006)10.7554/eLife.03778.007Figure 2---figure supplement 1.AMOT p130, AMOTL1 and AMOTL2 bind directly and specifically to NEDD4L and HIV-1 Gag~∆p6~.(**A**) OSF-AMOT p130, OSF-AMOTL1, and OSF-AMOTL2 bind NEDD4L. Recombinant OSF-GFP (specificity control, lanes 2 and 6), OSF-AMOT p130 (lanes 3 and 7), OSF-AMOTL1 (lanes 4 and 8), and OSF-AMOTL2 (lanes 5 and 9) were expressed, captured on STrEP-Tactin affinity matrices, and incubated with either a buffer control (lanes 2--5) or with a buffer containing 0.5 µM wild type NEDD4L (lanes 6--9). Matrix-bound proteins were released by boiling in denaturing buffer and detected by SDS-PAGE with Coomassie blue staining. Input NEDD4L (lane 1, 1.5% of total) is shown for reference. Asterisk denotes an OSF-AMOTL2 breakdown product that co-migrates with NEDD4L. A representative image from two independent repetitions is shown. (**B**) OSF-AMOT p130, OSF-AMOTL1, and OSF-AMOTL2 bind Gag~∆p6~. Recombinant OSF-GFP (specificity control, lanes 2 and 6), OSF-AMOT p130 (lanes 3 and 7), OSF-AMOTL1 (lanes 4 and 8), and OSF-AMOTL2 (lanes 5 and 9) were expressed, captured on STrEP-Tactin affinity matrices, and incubated with either a buffer control (lanes 2--5) or buffers containing 1 µM Gag~∆p6~ (lanes 6--9). Matrix-bound proteins were released by boiling in denaturing buffer and detected by SDS-PAGE with Coomassie blue staining. Input Gag~∆p6~ (lane 1, 2% of total) is shown for reference. A representative image from two independent repetitions is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.007](10.7554/eLife.03778.007)

Analogous pull-down experiments were performed to test whether AMOT binds HIV-1 Gag~Δp6~. Removing the p6 region facilitates Gag protein expression and purification, and is not expected to interfere with any biologically relevant interactions because NEDD4L potently stimulates HIV-1 Gag~Δp6~ release from cells ([@bib8]; [@bib50]). As shown in [Figure 2B](#fig2){ref-type="fig"}, HIV-1 Gag~Δp6~ bound immobilized OSF-AMOT p130, but did not bind an immobilized OSF-GFP control (compare lanes 4 and 8). This interaction did not appear to be mediated by nucleic acids because the affinity-purified OSF-AMOT p130 protein was pre-washed with high salt solution to remove any bound nucleic acid (see 'Materials and methods'), and because the interaction was maintained, albeit at slightly lower levels, even when immobilized OSF-AMOT p130 was incubated with high concentrations of RNase that were sufficient to eliminate other RNA-mediated Gag-protein interactions (not shown). Gag~Δp6~ and NEDD4L appeared to bind OSF-AMOT p130 independently because their binding levels did not change significantly when all three proteins were incubated together (compare lanes 8 and 9 to lane 10).

AMOT is the founding member of the human motin family, which also includes Angiomotin-like protein 1 (AMOTL1) and Angiomotin-like protein 2 (AMOTL2) ([@bib35]). AMOTL1 and AMOTL2 share 52% and 45% pair-wise sequence identity with AMOT p130, and both contain the N-terminal extension and PPXY motifs that are present in AMOT p130 but absent in AMOT p80 ([Figure 1A](#fig1){ref-type="fig"}). Pull-down experiments demonstrated that AMOTL1 and AMOTL2 also bind both NEDD4L and HIV-1 Gag~Δp6~ ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Thus, AMOT p130 binds directly and specifically to both NEDD4L and HIV-1 Gag, and these binding activities are shared by the other two human motins.

AMOT p130 overexpression enhances NEDD4L stimulation of HIV-1 budding {#s2-3}
---------------------------------------------------------------------

Co-expression experiments were performed to test whether AMOT and NEDD4L can cooperate in stimulating HIV-1 release ([Figure 3](#fig3){ref-type="fig"}). These experiments employed the crippled HIV-1~ΔPTAP,\ ΔYP~ viral expression construct, which lacks functional PTAP and YPX~n~L late domains and is therefore particularly responsive to cellular NEDD4L activity ([@bib8]; [@bib50]). As expected, HIV-1~ΔPTAP,\ ΔYP~ was poorly released from control 293T cells, as measured by western blot that detected virion-associated CA and MA proteins ([Figure 3](#fig3){ref-type="fig"}, upper right panel, lane 1), and low viral titers (lower right panel, lane 1). Overexpression of HA-AMOT p130 increased the levels of the full-length protein (and presumptive breakdown products were also evident, left panel 1, compare lanes 1 and 2). AMOT p130 overexpression modestly increased HIV-1~ΔPTAP.ΔYP~ release and infectivity (right panels compare lanes 1 and 2, 1.7-fold increases in both release and infectivity), without significantly altering the intracellular levels of Gag (left, panel 4, compare lanes 1 and 2) or a control cellular protein (GAPDH, left panel 3, compare lanes 1 and 2). Thus, AMOT p130 overexpression stimulates HIV-1~ΔPTAP,\ ΔYP~ release and infectivity, but the effect is modest.10.7554/eLife.03778.008Figure 3.AMOT p130 stimulates NEDD4L-dependent release of HIV-1~ΔPTAP,\ ΔYP~.Left panels are western blots showing 293T cellular levels of endogenous AMOT and exogenous HA-AMOT p130 proteins (panel 1, anti-AMOT), exogenous FLAG-NEDD4L (panel 2, anti-FLAG), endogenous GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag~ΔPTAP,\ ΔYP~ proteins (panel 4, anti-MA and anti-CA). Cells were co-transfected with expression vectors for HIV-1~ΔPTAP,\ ΔYP~ (lanes 1--6), FLAG-NEDD4L proteins (lanes 3--6, with wild type (WT) FLAG-NEDD4L in lanes 3 and 4 and FLAG-NEDD4L~ΔWW~, in lanes 5 and 6), and wild type HA-AMOT p130 (lanes 2, 4 and 6) or an empty vector control (lanes 1, 3, and 5). Right panels show corresponding levels of extracellular, virion-associated CA^Gag^ and MA^Gag^ proteins (panel 1, anti-MA and anti-CA) and viral titers (panel 2, IU denotes 'infectious units'). Here and in subsequent figures: (1) error bars denote standard deviations between independent repetitions of the experiment, n = 5 in this case, and (2) numbers within the blots show integrated intensities of the CA band intensities (relative to the value in the control experiment, set to 1.0). Here and throughout significance is denoted by: NS, not significant (p \> 0.05); \*0.05 \> p \> 0.01; \*\*p \< 0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.008](10.7554/eLife.03778.008)10.7554/eLife.03778.009Figure 3---figure supplement 1.Dose-dependent AMOT p130 stimulation of NEDD4L-dependent release of HIV-1~ΔPTAP,\ ΔYP~.Left panels are western blots showing 293T cellular levels of endogenous AMOT and exogenous HA-AMOT p130 proteins (panel 1, anti-AMOT), exogenous FLAG-NEDD4L (panel 2, anti-FLAG), GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag~ΔPTAP,\ ΔYP~ proteins (panel 4, anti-MA and anti-CA). Cells were co-transfected with expression vectors for HIV-1~ΔPTAP,\ ΔYP~ (lanes 1--8), FLAG-NEDD4L (lanes 2--8), and increasing quantities of an AMOT p130 expression construct (lanes 3--8, 0.25--1.5 μg DNA). Cells were also co-transfected with empty vectors as necessary to keep total DNA levels constant (3 μg DNA total). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, anti-MA and anti-CA) and viral titers (lower panel), n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.009](10.7554/eLife.03778.009)10.7554/eLife.03778.010Figure 3---figure supplement 2.The AMOT p130 isoform specifically stimulates NEDD4L-dependent release of HIV-1~ΔPTAP,\ ΔYP~.Left panels are western blots showing 293T cellular levels of endogenous AMOT, exogenous p80 and exogenous HA-AMOT p130 proteins (panel 1, anti-AMOT), exogenous FLAG-NEDD4L (panel 2, anti-FLAG), GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag~ΔPTAP,\ ΔYP~ proteins (panel 4, anti-MA and anti-CA). Cells were co-transfected with expression vectors for HIV-1~ΔPTAP,\ ΔYP~ (lanes 1--6), AMOT p80 (lanes 2 and 5), AMOT p130 (lanes 3 and 6) and FLAG-NEDD4L (lanes 4--6). Cells were also co-transfected with empty vectors as necessary to keep total DNA levels constant (2.5 μg DNA total). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, anti-MA and anti-CA) and viral titers (lower panel), n = 4.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.010](10.7554/eLife.03778.010)

As seen previously, FLAG-NEDD4L overexpression also stimulated HIV-1~ΔPTAP,\ ΔYP~ release ([Figure 3](#fig3){ref-type="fig"}, right panel 1, compare lanes 1 and 3, 3.2-fold stimulation) and infectivity (right panel 2, compare lanes 1 and 3, 5.3-fold stimulation), and also largely rescued the HIV-1~ΔPTAP,\ ΔYP~ Gag processing defects (left panel 4, compare lane 3 to lanes 1 and 2, and note the reduction in p41 and p25 Gag processing intermediates) ([@bib8]; [@bib50]). Co-overexpression of both HA-AMOT p130 and FLAG-NEDD4L further increased HIV-1~ΔPTAP,\ ΔYP~ release (right panel 1, lane 4, sixfold increase over basal levels) and infectivity (right panel 2, lane 4, 14-fold increase over basal levels). As shown in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, the degree of hyper-stimulation correlated positively with AMOT p130 expression levels, until an inhibitory level was reached. In contrast to wild type NEDD4L, the NEDD4L~ΔWW~ mutant stimulated HIV-1~ΔPTAP,\ ΔYP~ release and infectivity only very modestly ([Figure 3](#fig3){ref-type="fig"}, right panels, compare lanes 5 and 3) and did not synergize with AMOT p130 (right panels, compare lanes 6 and 5). Similarly, the shorter AMOT p80 isoform, which lacks the PPXY motifs found in the N-terminal domain of AMOT p130, failed to synergize with NEDD4L in stimulating virus release and infectivity, and instead modestly *reduced* NEDD4L stimulation, probably by dominantly inhibiting endogenous AMOT p130 activity ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, compare lanes 4--6). These data indicate that AMOT p130 and NEDD4L cooperate in stimulating HIV-1~ΔPTAP,\ ΔYP~ release and infectivity.

AMOT p130 is required for NEDD4L stimulation of HIV-1 budding {#s2-4}
-------------------------------------------------------------

siRNA depletion experiments were performed to determine whether AMOT was also *necessary* for NEDD4L stimulation of HIV-1~ΔPTAP,\ ΔYP~ release and infectivity. We used an siRNA that targeted both AMOT isoforms and reduced cellular AMOT p130 and p80 levels by at least fivefold ([Figure 4](#fig4){ref-type="fig"}, left panel 1, compare lanes 1 and 2 and lanes 3 and 4). AMOT depletion reduced the already low levels of virus release and infectivity even further, to near background levels ([Figure 4](#fig4){ref-type="fig"}, right panels, compare lanes 1 and 2, 7.5-fold infectivity reduction). Cellular levels of Gag and a GAPDH control were unaffected by this treatment (left panels 3 and 4, compare lanes 1 and 2), although AMOT depletion reduced cellular protein levels slightly in some repetitions (not shown).10.7554/eLife.03778.011Figure 4.AMOT p130 is required for NEDD4L-stimulated release of HIV-1~ΔPTAP,\ ΔYP~.Left panels are western blots showing 293T cellular levels of endogenous AMOT and exogenous HA-AMOT p130 proteins (panel 1, anti-AMOT), exogenous FLAG-NEDD4L (panel 2, anti-FLAG), endogenous GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag~ΔPTAP,\ ΔYP~ proteins (panel 4, anti-MA and anti-CA). Cells were co-transfected with a control siRNA (lanes 1 and 3) or with an siRNA that depleted both AMOT p130 and p80 (lanes 2 and 4--6), with expression vectors for HIV-1~ΔPTAP,\ ΔYP~ (lanes 1--6), and with FLAG-NEDD4L (lanes 3--6) or an empty vector control (lanes 1 and 2), and with siRNA-resistant expression constructs for HA-AMOT p130 proteins (with wild type HA-AMOT p130 in lane 5 and an HA-AMOT p130~ΔPPXY~ protein carrying inactivating point mutations in the three PPXY motifs in lane 6). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel), n = 6.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.011](10.7554/eLife.03778.011)10.7554/eLife.03778.012Figure 4---figure supplement 1.Dose-dependent AMOT p130 rescue of HIV-1 release from cells depleted of endogenous AMOT.Left panels are western blots showing 293T cellular levels of endogenous AMOT and exogenous HA-AMOT p130 proteins (panel 1, anti-AMOT), exogenous FLAG-NEDD4L (panel 2, anti-FLAG), GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag proteins (panel 4, anti-MA and anti-CA). Cells were co-transfected with a control siRNA (lanes 1 and 3) or with an siRNA that depleted both AMOT p130 and p80 (lanes 2 and 4--10), with expression vectors for HIV-1~ΔPTAP,\ ΔYP~ (lanes 1--10), for FLAG-NEDD4L (lanes 3--10), and with increasing quantities of an siRNA-resistant AMOT p130 construct (lanes 5--10, 0.25--1.5 μg DNA). Cells were also co-transfected with empty vectors as necessary to keep total DNA levels constant (3 μg DNA total). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel), n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.012](10.7554/eLife.03778.012)10.7554/eLife.03778.013Figure 4---figure supplement 2.The AMOT p130 isoform specifically stimulates NEDD4L-dependent release of HIV-1~ΔPTAP,\ ΔYP~.Left panels are western blots showing 293T cellular levels of endogenous AMOT and exogenous HA-AMOT p130 or AMOT p80 proteins (panel 1, anti-AMOT), exogenous FLAG-NEDD4L (panel 2, anti-FLAG), endogenous GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag~ΔPTAP,\ ΔYP~ proteins (panel 4, anti-MA and anti-CA). Cells were transfected with a control siRNA (lanes 1 and 3) or with an siRNA that depleted both AMOT p130 and p80 (lanes 2 and 4--7). Cells were co-transfected with expression vectors for HIV-1~ΔPTAP,\ ΔYP~ (lanes 1--7), FLAG-NEDD4L (lanes 3--7), and siRNA-resistant expression constructs for AMOT p80 (lane 5), HA-AMOT p130 (lane 6) or both (lane 7). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel), n = 6.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.013](10.7554/eLife.03778.013)

AMOT depletion blocked the ability of NEDD4L to stimulate HIV-1~ΔPTAP,\ ΔYP~ release and infectivity ([Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplements 1, 2](#fig4s1 fig4s2){ref-type="fig"}). In the control case, NEDD4L overexpression stimulated HIV-1~ΔPTAP,\ ΔYP~ release ([Figure 4](#fig4){ref-type="fig"}, right panels, compare lanes 1 and 3, 4.1-fold infectivity increase). However, virus release was reduced to the levels seen in untreated control cells when endogenous AMOT p80 and p130 proteins were simultaneously depleted (compare lanes 2--4). Similar results were observed for a second siRNA that targeted both AMOT isoforms (not shown). Thus, AMOT is required for NEDD4L stimulation of HIV-1~ΔPTAP,\ ΔYP~ release.

Rescue experiments with exogenous siRNA-resistant AMOT expression constructs were performed to confirm the specificity of the AMOT depletion and to test the requirements for AMOT function. Re-expression of AMOT p130 completely rescued the block to virus release and infectivity imposed by AMOT depletion ([Figure 4](#fig4){ref-type="fig"}, right panels, compare lanes 5 and 4), restoring viral infectivity to a level that was actually slightly higher than the control (compare lanes 3 and 5). The degree of rescue generally correlated positively with AMOT p130 re-expression levels, and peaked at levels that approximated those of the native endogenous protein ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, lane 8). In contrast, an AMOT p130 protein that lacked the three N-terminal PPXY motifs failed to rescue NEDD4L-dependent HIV-1~ΔPTAP,\ ΔYP~ release ([Figure 4](#fig4){ref-type="fig"}, AMOT p130~ΔPPXY~, right panels, compare lanes 6 and 5). Similarly, re-expression of an siRNA-resistant AMOT p80 construct also failed to rescue virus release and infectivity ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, right panels, compare lanes 4 and 5), unless exogenous AMOT p130 was present ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, right panels, lane 7). Hence, NEDD4L stimulation of HIV-1~ΔPTAP,\ ΔYP~ release and infectivity requires the presence of an AMOT p130 protein that can bind NEDD4L, but is not significantly affected by AMOT proteins that cannot bind NEDD4L, including AMOT p80.

AMOT p130 is required for efficient release of wild type HIV-1 {#s2-5}
--------------------------------------------------------------

siRNA depletion and rescue experiments were also performed to test whether AMOT p130 is required for release and infectivity of *wild type* HIV-1. In control experiments, depletion of either of the well-characterized HIV-1 budding factors, ALIX and TSG101, reduced virus release and infectivity, although the effects were much greater for TSG101 depletion, as reported previously ([Figure 5](#fig5){ref-type="fig"}, right panels, compare lanes 2 and 3 to lane 1) ([@bib15]). AMOT depletion also significantly reduced both HIV-1 release and infectivity ([Figure 5](#fig5){ref-type="fig"}, right panels, compare lane 4 to lane 1, eightfold reduction in infectivity and 2.5-fold reduction in release). The magnitudes of these effects were intermediate between those seen for depletion of TSG101 (20-fold reduction in infectivity and threefold reduction in virion release) and ALIX (1.5-fold reduction in infectivity and insignificant reduction in virion release). Importantly, the detrimental effects of AMOT p130 depletion were almost completely rescued by re-expression of wild type AMOT p130 (compare lanes 1, 4 and 5) but not by the mutant AMOT p130~ΔPPXY~ protein (lane 6). These experiments demonstrate that AMOT p130 is required for efficient release of wild type HIV-1 from 293T cells and mutations that abolish NEDD4L binding block the ability of AMOT p130 to function in virus release.10.7554/eLife.03778.014Figure 5.AMOT p130 is required for efficient release of wild type HIV-1.Left panels are western blots showing 293T cellular levels of endogenous ALIX (panel 1, anti-ALIX), TSG101 (panel 2, anti-TSG101), AMOT (panel 3, anti-AMOT), GAPDH (panel 4, anti-GAPDH, loading control) and levels of HIV-1 Gag proteins (panel 5, anti-MA and anti-CA). Cells were co-transfected with a control siRNA (lane 1) or with an siRNA that depleted ALIX (lane 2), TSG101 (lane 3) or AMOT p130 and p80 (lanes 4--6), with expression vectors for wild type HIV-1 (lanes 1--6) and with an siRNA-resistant expression constructs for HA-AMOT p130 proteins (with wild type HA-AMOT p130 in lane 5 and an HA-AMOT p130~ΔPPXY~ protein with inactivating point mutations in all three PPXY motifs in lane 6). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel), n = 4.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.014](10.7554/eLife.03778.014)

AMOT stimulates HIV-1 release from HeLa cells {#s2-6}
---------------------------------------------

AMOT mRNA is expressed in 293T cells, as well as in white blood cells and lymphoid tissues that are the natural hosts for HIV-1 infection ([@bib35]). In contrast, HeLa cells reportedly express little or no AMOT mRNA, although they do express AMOTL2 mRNA ([@bib35]). We confirmed that endogenous AMOT protein levels are at least 10-fold lower in HeLa cells than in 293T cells ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). This observation begs the question of how HIV-1 can be released from a cell type that lacks AMOT, and this issue is particularly relevant because HeLa cells are commonly used to study HIV-1 assembly. We therefore tested the effects of AMOT p130 expression on HIV-1 release and infectivity in HeLa cells. As shown in [Figure 6A](#fig6){ref-type="fig"}, AMOT p130 expression increased HIV-1 release from HeLa cells in a dose-dependent fashion, up to 15-fold at the highest levels of AMOT tested (right panel 1, compare lanes 1 and 5). Viral titers similarly increased with AMOT expression in a dose-dependent fashion, although the overall effects were less dramatic (right panel 2, compare lanes 1--5, threefold infectivity increase). Thus, HIV-1 release from wild type HeLa cells is suboptimal, and can be enhanced by expression of AMOT p130.10.7554/eLife.03778.015Figure 6.AMOT p130 stimulates release of HIV-1 from HeLa and Jurkat T cells.(**A**) Left panels are western blots showing HeLa cellular levels of endogenous AMOT p130 and exogenous HA-AMOT p130 (panel 1, anti-AMOT), endogenous GAPDH (panel 2, anti-GAPDH, loading control) and HIV-1 Gag proteins (panel 3, anti-MA and anti-CA). HeLa cells were co-transfected with expression vectors for HIV-1 (lanes 1--5), and with increasing concentrations of an expression construct for HA-AMOT p130 (0--4 μg DNA in lanes 1--5). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel), n = 4. (**B**) Levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel). Jurkat T cells were co-transfected with expression vectors for HIV-1 (lanes 1--5), together with a control vector (lane 1) or expression vectors for wild type HA-AMOT p130 (lanes 2 and 3, 5 and 10 µg DNA respectively) or an HA-AMOT p130~ΔPPXY~ protein with inactivating point mutations in the three PPXY motifs (lanes 4 and 5, 5 and 10 µg DNA respectively), n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.015](10.7554/eLife.03778.015)10.7554/eLife.03778.016Figure 6---figure supplement 1.HeLa cells express little or no AMOT.Western blots showing endogenous AMOT p130 and p80 expression levels in 293T cells (lanes 1--4) and in HeLa cells (lanes 5--8). Increasing numbers of cell equivalents were added as indicated (ranging from 1.5 × 10^5^ cells in lanes 1 and 5 to 1.2 × 10^6^ cells in lanes 4 and 8). Upper and lower panels show lighter and darker exposures of the same blot. Image is representative of two independent repetitions of this experiment.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.016](10.7554/eLife.03778.016)

AMOT also stimulates HIV-1 release from Jurkat T cells {#s2-7}
------------------------------------------------------

T cells are natural hosts for HIV-1 infection, and AMOT mRNA is present in these cells, including Jurkat T cells ([@bib57]; [@bib44]). To determine whether AMOT p130 can function in virus release from Jurkat T cells, we tested whether expressing exogenous AMOT p130 expression stimulated HIV-1 release and infectivity. As shown in [Figure 6B](#fig6){ref-type="fig"}, AMOT p130 expression increased HIV-1 release from Jurkat T cells in a dose-dependent fashion, with up to 16-fold stimulation observed at the highest levels of AMOT p130 tested (panel 1, compare lanes 1--3). Viral titers similarly increased in a dose-dependent fashion (panel 2, compare lanes 1--3, sevenfold infectivity increase). Western blots confirmed that virus expression levels were the same in all cases (not shown), but AMOT p130 expression levels were below our detection limits in this cell type. We therefore also tested the effects of overexpressing the mutant AMOT p130~ΔPPXY~ protein. Unlike wild type AMOT p130, AMOT p130~ΔPPXY~ failed to stimulate virus release, and actually reproducibly *decreased* viral titers as compared to the untreated control (compare lanes 4 and 5 to lane 1). We speculate that this effect again reflects dominant inhibition of endogenous AMOT p130. Regardless, our data indicate that AMOT p130 also stimulates virus release and infectivity from T cells, which are natural targets of HIV-1 infection. Consistent with this conclusion, a global shRNA screen for host cofactors revealed that Jurkat T cells transduced with an shRNA that targeted AMOT were protected against HIV cytotoxicity ([@bib57]). This observation implies that AMOT contributes to HIV-1 replication in cultured Jurkat T cells, although the role of AMOT in HIV-1 replication was not characterized further in that study. ([@bib57]).

Other human motins can also stimulate HIV-1 release {#s2-8}
---------------------------------------------------

siRNA depletion/rescue experiments were performed to test whether other motin family members can substitute for AMOT p130 in supporting release of wild type HIV-1 ([Figure 7](#fig7){ref-type="fig"}). In control experiments, HIV-1 release and infectivity were again decreased by depletion of endogenous AMOT from 293T cells (right panels, compare lanes 1 and 2, fivefold infectivity reduction). As expected, these effects were largely rescued by expression of exogenous siRNA-resistant AMOT p130 (right panels, compare lanes 2 and 3). Expression of either AMOTL1 or AMOTL2 also significantly rescued HIV-1 release and infectivity (right panels, compare lanes 4 and 5 to lanes 2 and 3). Hence, both AMOT-like proteins can facilitate HIV-1 release in the absence of endogenous AMOT p130. Neither AMOTL1 nor AMOTL2 was quite as effective as AMOT p130 in rescuing HIV-1 infectivity in this assay, possibly because these proteins are intrinsically less active than AMOT p130 and/or because they were expressed at lower levels (left panel 2, compare lanes 3--5).10.7554/eLife.03778.017Figure 7.AMOTL1 and AMOTL2 can substitute for AMOT p130 in HIV-1 release.Left panels are western blots showing 293T cellular levels of endogenous AMOT and exogenous HA-AMOT p130 proteins (panel 1, anti-AMOT), exogenous HA-AMOT p130, HA-AMOTL1 or HA-AMOTL2 proteins (panel 2, anti-HA), endogenous GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag proteins (panel 4, anti-MA and anti-CA). Cells were co-transfected with a control siRNA (lane 1) or with an siRNA that depleted AMOT p130 and AMOT p80 (lanes 2--5), and with expression vectors for HIV-1 (lanes 1--5), with siRNA-resistant expression constructs for AMOT p130 (lane 3), AMOTL1 (lane 4) or AMOTL2 (lane 5). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel), n = 4.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.017](10.7554/eLife.03778.017)10.7554/eLife.03778.018Figure 7---figure supplement 1.AMOTL2 can stimulate NEDD4L-dependent release of HIV-1~ΔPTAP,\ ΔYP~ and rescue HIV-1~ΔPTAP,\ ΔYP~ release from cells depleted of endogenous AMOT.(**A**) AMOTL2 stimulates NEDD4L-dependent release of HIV-1~ΔPTAP,\ ΔYP~. Left panels are western blots showing 293T cellular levels of exogenous HA-AMOT p130, HA-AMOTL1 or HA-AMOTL2 proteins (panel 1, anti-HA), exogenous FLAG-NEDD4L (panel 2, anti-FLAG), GAPDH (panel 3, anti-GAPDH, loading control) and HIV-1 Gag proteins (panel 4, anti-MA and anti-CA). Cells were co-transfected with expression vectors for HIV-1~ΔPTAP/ΔYP~ (lanes 1--8), FLAG-NEDD4L (lanes 5--8), and either HA-AMOT p130 (lanes 2 and 6), HA-AMOTL1 (lanes 3 and 7) or HA-AMOTL2 (lanes 4 and 8). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel) and viral titers (lower panel), n = 3. (**B**) AMOTL2 can rescue HIV-1~ΔPTAP,\ ΔYP~ release from 293T cells depleted of endogenous AMOT. Left panels are western blots showing cellular levels of endogenous AMOT and exogenous HA-AMOT proteins (panel 1, anti-AMOT), exogenous HA-AMOT p130, HA-AMOTL1 or HA-AMOTL2 (panel 2, anti-HA), exogenous FLAG-NEDD4L (panel 3, anti-FLAG), GAPDH (panel 4, anti-GAPDH, loading control) and HIV-1 Gag proteins (panel 5, anti-MA and anti-CA). Cells were co-transfected with a control siRNA (lanes 1 and 3) or with an siRNA that depleted both AMOT p130 and p80 (lanes 2 and 4--7), with expression vectors for HIV-1 (lanes 1--7), FLAG-NEDD4L (lanes 3--7), and either an siRNA-resistant HA-AMOT p130 expression construct (lane 5), or expression constructs for HA-AMOTL1 (lane 6), or HA-AMOTL2 (lane 7). Right panels show corresponding levels of extracellular virion-associated Gag proteins (upper panel, western blot, anti-MA and anti-CA) and viral titers (lower panel), n = 4.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.018](10.7554/eLife.03778.018)

We also tested whether the other AMOT family members could cooperate with NEDD4L in stimulating release of the crippled HIV-1~ΔPTAP,\ ΔYP~ virus ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}) and whether AMOTL1 and AMOTL2 could rescue the block to NEDD4L stimulation of HIV-1~ΔPTAP,\ ΔYP~ release imposed by depletion of endogenous AMOT ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). AMOTL2 strongly stimulated/rescued HIV-1~ΔPTAP,\ ΔYP~ release in both of these assays, albeit slightly less efficiently than AMOT p130 ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}, compare lane 8 to lanes 5 and 6 and [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}, compare lane 7 to lanes 4 and 5). In contrast, AMOTL1 exhibited little or no activity in either assay ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}, compare lane 7 to lanes 5 and 6 and [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}, compare lane 6 to lanes 4 and 5). Thus, AMOTL2 could substitute for AMOT p130 in three different virus release assays, whereas AMOTL1 was slightly less active than AMOT in the release of wild type HIV-1, and failed to stimulate release of the 'crippled' HIV-1~ΔPTAP,\ ΔYP~ construct.

AMOT depletion inhibits an early stage of HIV-1 budding {#s2-9}
-------------------------------------------------------

Scanning and transmission electron microscopy (SEM and TEM, respectively) were used to visualize the stage at which AMOT depletion inhibited HIV-1 assembly or release ([Figures 8, 9](#fig8 fig9){ref-type="fig"}). SEM imaging was initially performed because this method can survey the entire cell surface and thereby identify global changes in virion assembly and budding profiles. SEM analyses were performed on 293T cells that expressed HIV-1 and were treated with either: (1) a control siRNA, (2) an siRNA that depleted TSG101 (positive control), or (3) an siRNA that depleted AMOT. As expected, viruses budding from control siRNA-treated cells were detectable but rare (e.g., [Figure 8A--C](#fig8){ref-type="fig"}). In contrast, large numbers of assembling virions were visible on the surfaces of cells that lacked TSG101 ([Figure 8D--F](#fig8){ref-type="fig"}) or that lacked AMOT ([Figure 8G--I](#fig8){ref-type="fig"}). We also observed that the arrested virions tended to cluster in the center of cells lacking AMOT, whereas they were more evenly distributed across the surfaces of cells lacking TSG101. The dramatic increase in the numbers of arrested budding virions implies that AMOT, like TSG101, must function following the initial stages of Gag assembly, but prior to viral membrane fission.10.7554/eLife.03778.019Figure 8.AMOT p130 is required for HIV-1 assembly/budding.Scanning electron microscopic (SEM) images of HIV virions budding from 293T cells depleted with a control siRNA (**A**--**C**), depleted of TSG101 (**D**--**F**) or depleted of AMOT (**G**--**I**). Successive images across each row show expansions of the adjacent boxed regions, and scale bars are 500 nm in all cases. Arrows in panel (**C**) highlight budding wild type HIV-1 virions.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.019](10.7554/eLife.03778.019)10.7554/eLife.03778.020Figure 9.AMOT p130 is required for an early stage of HIV-1 assembly/budding.(**A**) Transmission electron microscopic (TEM) images of HIV virions budding from 293T cells depleted of TSG101. Panel 1: wide view. Panel 2: expanded view. Scale bars here and in part B are 100 nm. (**B**) TEM images of HIV virions budding from 293T cells depleted of AMOT p130 and p80. Panel 1: wide view. Panel 2: expanded view. (**C**) Quantification of the release and maturation status of HIV-1 virions associated with cells that were treated with a control siRNA (black bars), depleted of TSG101 (red), depleted of AMOT (teal), or depleted of AMOT and re-expressing AMOT p130 from an siRNA-resistant construct (light blue). This experiment was repeated twice with similar results, and error bars were derived by quantifying three separate sets of \>100 virions each from one of the experiments. (**D**) Quantification of the completeness of virions budding from cells treated with a control siRNA (black triangles), depleted of TSG101 (red squares), or depleted of AMOT (teal diamonds). The extent of the Gag shell arc (in degrees) was measured from TEM images of 500 budding virions of each type, the measurements were binned into the intervals shown below the x-axis, and the virion numbers in each bin are shown in the plot.**DOI:** [http://dx.doi.org/10.7554/eLife.03778.020](10.7554/eLife.03778.020)

TEM experiments were performed to characterize how virus assembly/budding arrested in the absence of AMOT. These experiments again visualized HIV-1 budding from 293T cells treated with a control siRNA, an siRNA that depleted TSG101 (positive control), an siRNA that depleted AMOT, or an siRNA that depleted endogenous AMOT together with an siRNA-resistant construct that re-expressed wild type AMOT p130 (rescue control). Culture supernatants were removed from the virus producing cells and the adherent cells were fixed while still attached to the culture dish in order to maximize the numbers of cell-associated virions. Fixed cells were harvested, embedded in resin, thin sectioned, stained, and visualized by TEM. Cell-associated virions observed in these experiments were scored as being either: (1) mature (discernable conical or condensed cores), (2) immature (discernable immature Gag shells), or (3) budding (contiguous cellular and viral membranes).

HIV-1 virions associated with wild type cells were usually mature (76 ± 5%, see [Figure 9C](#fig9){ref-type="fig"}), but immature and budding virions were also observed (9 ± 3% and 15 ± 5%, respectively). As expected, TSG101 depletion induced a strong virus budding defect, with the majority of detected virions arrested at the budding stage (67 ± 7%, shown in [Figure 9A](#fig9){ref-type="fig"} and quantified in [Figure 9C](#fig9){ref-type="fig"}). In addition, the ratio of mature (10 ± 6%) to immature (23 ± 2%) virions (1:2.3) was much lower than in the control case (1:0.1), consistent with previous reports that TSG101 is also required for efficient Gag processing and maturation ([@bib17]; [@bib16]; [@bib31]).

AMOT depletion also inhibited virus release, as reflected in a large increase in the percentage of virions detected at the budding stage (72 ± 6%, shown in [Figure 9B](#fig9){ref-type="fig"} and quantified in [Figure 9C](#fig9){ref-type="fig"}). In this case, however, the virions that were released exhibited a normal ratio of mature:immature virions (25 ± 5% vs 3 ± 2%; 1:0.1). Importantly, the budding defect seen in cells lacking endogenous AMOT was almost completely rescued by re-expression of the siRNA-resistant AMOT p130 ([Figure 9C](#fig9){ref-type="fig"}), so that the majority of virions were now mature (70 ± 5% vs 76 ± 5% in the control), and budding virion levels were nearly normal (26 ± 9% vs 15 ± 5% in the control). Thus, AMOT depletion blocks virus release at the assembly/budding stage, but does not inhibit Gag processing or virion maturation.

It was also striking that AMOT depletion caused virion assembly/budding to arrest at an earlier stage than TSG101 depletion. This difference can be seen in the EM images shown in [Figure 9A,B](#fig9){ref-type="fig"}, where most of the virions in TSG101-depleted cells exhibit the characteristic 'lollipop' morphology associated with a late assembly/membrane fission defect ([Figure 9A](#fig9){ref-type="fig"}), whereas most of the virions budding from AMOT-depleted cells exhibit a 'half-moon' morphology in which the nascent viral membrane and Gag shell are incomplete ([Figure 9B](#fig9){ref-type="fig"}). This observation was quantified by imaging 500 budding HIV-1 virions from: (1) wild type cells (control), (2) cells depleted of TSG101, and (3) cells depleted of AMOT. The arc formed by the Gag shell was measured manually for each budding virion, and the 500 measurements for each condition were then binned in 15° intervals and displayed graphically ([Figure 9D](#fig9){ref-type="fig"}).

The Gag arc distribution of control virions budding from wild type cells exhibited two similarly sized peaks; one in which the Gag shells covered an arc of ∼155**°**, and another in which the Gag shells covered an arc of ∼320**°**. These measurements indicate that virion assembly intermediates (or possibly dead-end products) appreciably accumulate at two different stages, suggesting that either stage can be rate limiting. In cells lacking TSG101, budding-arrested virions were much more prevalent and they typically arrested at very late stages of assembly, with the maximal population exhibiting a Gag shell arc of ∼320°. In cells lacking AMOT, arrested virions were again prevalent but they arrested at a much earlier stage, with the maximal population exhibiting a Gag shell arc of ∼165°. The dramatic increases in numbers of budding virions induced by depletion of TSG101 or AMOT can explain how the assembly phenotypes could distribute as single peaks in these cases, whereas virions budding from wild type cells (which were much rarer) distributed into two peaks. Our experiments reveal that HIV budding arrests at an earlier stage in the absence of AMOT than in the absence of TSG101, implying that AMOT acts at an earlier stage of virion morphogenesis.

Discussion {#s3}
==========

We have identified Angiomotin (AMOT) as a host protein required for efficient HIV-1 release. In the absence of AMOT, most virions arrested at a 'half-moon' stage in which a hemisphere of assembled Gag molecules distended the membrane, but did not form a spherical particle ([Figure 9](#fig9){ref-type="fig"}). The AMOT depletion phenotype was distinct from the defect induced by the absence of ESCRT factors, where virus budding arrested at a 'lollipop' stage in which nearly complete immature virions remained tethered to the host cell via thin membrane stalks. Thus, cellular factors facilitate (at least) two distinct steps in virion morphogenesis, with AMOT required to complete assembly/envelopment and the ESCRT machinery required for membrane fission. HIV-1 virions budding from control cells accumulated at both stages, suggesting that both steps can be kinetic bottlenecks (see [Figure 9D](#fig9){ref-type="fig"} and reference [@bib28]).

The Gag lattice organizes the virion and undoubtedly helps to drive membrane envelopment because pure recombinant Gag proteins can form spherical particles in vitro ([@bib5]). In cells, however, Gag appears to require additional activities to bend the membrane, extrude the particle, and sever the bud neck. The well-studied process of endocytic vesicle formation provides precedence for these additional requirements because clathrin alone can form spherical assemblies but nevertheless requires assistance from BAR domain-containing proteins to help bend membranes, and assistance from actin and dynamin to release the vesicle ([@bib54]). It is intriguing that AMOT p130 also contains a candidate BAR-like domain ([@bib21]) and can associate with F-actin (Ernkvist et al., 2006, [@bib13]; [@bib6]). The AMOT BAR-like domain can remodel membranes in vitro ([@bib21]), although it is not yet clear whether it functions as a classical or an inverse BAR domain. This distinction is mechanistically significant because classical BAR domains stabilize positive membrane curvature whereas inverse BAR domains stabilize negative curvature ([@bib34]), both of which are generated during enveloped virus assembly. In principle, the BAR domain could mediate AMOT p130 recruitment at the half-moon stage, once the nascent viral membrane has reached the proper degree of curvature. The BAR domain could also help drive the additional membrane curvature required to proceed to the lollipop stage. Similarly, F-actin recruitment and polymerization could help 'push' the virion toward the lollipop stage, although several recent studies argue strongly against an essential role for F-actin in HIV-1 assembly ([@bib3]; [@bib41]).

Our experiments indicate that another important AMOT p130 function is to recruit NEDD4L to sites of virus budding. In support of this idea, we have shown that: (1) the two proteins bind one another directly through interactions between the NEDD4L WW domains and PPXY elements present in the unique N-terminal region of the AMOT p130 isoform ([Figures 1, 2](#fig1 fig2){ref-type="fig"} and references [@bib52]; [@bib35]), (2) AMOT p130 can recruit NEDD4L to cellular membranes, and this activity requires the NEDD4L WW-AMOT p130 PPXY interactions (\[[@bib21]\] and our data not shown), (3) NEDD4L cannot stimulate release of 'crippled' HIV-1 constructs in the absence of AMOT ([Figure 4](#fig4){ref-type="fig"}), (4) NEDD4L mutants that cannot bind AMOT are also impaired in their ability to stimulate virus budding ([Figure 5](#fig5){ref-type="fig"}), (5) AMOT p80 and AMOT p130 PPXY mutants that cannot bind NEDD4L do not support virus budding ([Figures 3--6](#fig3 fig4 fig5 fig6){ref-type="fig"}) and (6) recombinant AMOT p130 and HIV-1 Gag proteins can bind one another directly, albeit weakly in vitro ([Figure 2B](#fig2){ref-type="fig"}), and could bind more robustly in cells owing to avidity and membrane topology effects.

Previous studies indicate that other retroviruses also employ distinct host factors to promote membrane envelopment and fission. The clearest example is the D-type Betaretrovirus Mason-Pfizer Monkey Virus (M-PMV), which forms spherical particles in the cytoplasm and then obtains its outer membrane and exits the cell by crossing the plasma membrane. M-PMV Gag contains two distinct late assembly domains that function non-redundantly: a PPPY motif that binds NEDD4 (and perhaps other NEDD4 family members), and a PSAP motif that binds TSG101/ESCRT-I ([@bib18]). PPPY and PSAP mutations induce strikingly different phenotypes: mutation of the PPPY motif causes virions to stack up against the plasma membrane where they fail to initiate membrane envelopment whereas virions lacking the PSAP motif acquire an envelope, but accumulate at the lollipop stage or are released as chains of membrane-tethered particles. These observations imply that Gag PPPY-NEDD4 complexes are required for early stages of membrane bending and envelopment, whereas Gag PSAP-ESCRT-I complexes recruit the ESCRT machinery to mediate membrane fission. Like other family members, NEDD4 binds AMOT ([@bib35]), and we therefore speculate that M-PMV may also recruit AMOT to facilitate membrane bending and particle envelopment. This would imply that viruses can recruit NEDD4-motin complexes by binding either member of the complex. The deltaretrovirus HTLV-I is another case where a PPXY motif appears to be required for an early step in particle envelopment and a PTAP motif may function at a later membrane fission step (\[[@bib29]; [@bib4]; [@bib20]\], but also see reference \[[@bib53]\]). Distinct roles for PPXY and PTAP motifs have not been delineated in other well-studied viruses that use both motifs, such as the gammaretrovirus Murine Leukemia Virus ([@bib59]) or the filovirus Ebola Virus ([@bib49]).

Although many details of HIV-1 assembly and budding remain to be elucidated, our data are consistent with a stepwise pathway in which: (1) AMOT p130 is recruited at the half-moon stage of HIV-1 assembly, perhaps by binding cooperatively to Gag and to appropriately curved membranes, (2) AMOT p130 promotes further membrane curvature and recruits NEDD4L via PPXY-WW domain interactions, (3) NEDD4L builds Lys-63-linked ubiquitin chains on the viral Gag protein (and/or other nearby substrates), (4) the juxtaposition of Gag late assembly domains and Lys-63-linked Ub chains creates high affinity binding sites for the early-acting ESCRT factors, TSG101 and ALIX, and (5) these factors then recruit the downstream ESCRT-III and VPS4 components required to effect membrane scission. This model is attractive because: (1) our work shows that AMOT functions upstream of the ESCRT pathway, (2) AMOT appears to function as a NEDD4L adaptor (see above), (3) ubiquitin transfer is required for efficient HIV-1 release ([@bib30]), (4) NEDD4L builds Lys-63-linked ubiquitin chains and can use HIV-1 Gag as a substrate ([@bib55]; [@bib43]), and (5) both TSG101/ESCRT-I and ALIX have ubiquitin binding activities. The ALIX activity is specific for Lys-63-linked ubiquitin chains ([@bib10]; [@bib25]; [@bib39]), and ESCRT-I complexes also have multiple ubiquitin binding sites, although linkage specificity has not been observed ([@bib46]; [@bib1]; [@bib32]). Cooperative binding to the late domains and ubiquitin could explain how ALIX and TSG101/ESCRT-I can be efficiently recruited, despite making intrinsically weak interactions with the p6^Gag^ late assembly domains. The proposed sequence of events could also provide a 'timing' mechanism for recruiting (or activating) these early-acting ESCRT proteins to function at a late stage of virion assembly, although the precise timing of early-acting ESCRT recruitment remains to be clarified because published reports differ on this issue ([@bib24]; [@bib27]).

All enveloped viruses must bend and remodel membranes as they bud, and AMOT requirements may therefore be quite general. Indeed, AMOTL1 has been shown to bind the M protein of PIV5 and to be required for the efficient, ubiquitin-dependent release of this virus ([@bib40]). Motin family members therefore contribute to the assembly of at least two highly diverged enveloped viruses; the paramyxovirus PIV5 and the lentivirus HIV-1. This suggests that AMOT proteins, like the ESCRT machinery, may provide general activities required for the assembly and release of a variety of different enveloped viruses.

Materials and methods {#s4}
=====================

Plasmids, siRNA constructs and antibodies {#s4-1}
-----------------------------------------

Expression constructs, siRNA sequences, and antibodies are described in detail in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. Constructs for expressing wild type and mutant NEDD4L and AMOT proteins in *E. coli*, insect SF-9 cells, and human 293T cells were created by standard cloning and mutagenesis methods, with detailed methods available upon request. All of the new expression constructs used in our studies have been deposited in the public DNASU plasmid repository (<http://dnasu.org/DNASU/Home.jsp>).

Affinity purification and mass spectrometric identification of AMOT {#s4-2}
-------------------------------------------------------------------

For the experiment shown in [Figure 1B](#fig1){ref-type="fig"}, an empty vector control or a pCAG-OSF-NEDD4L expression vector ([@bib37]) expressing NEDD4L with an N-terminal One-STrEP-FLAG (OSF) affinity tag was transfected into 293T cells (calcium phosphate method, 2 × 10 cm plates each, 25 μg DNA/plate). After 48 hr, cells from each sample were collected by scraping, pooled, washed three times with PBS (1.5 mM KH~2~PO~4~, 155 mM NaCl, 2.7 mM Na~2~HPO~4~, pH 7.4), and lysed with 500 μl Triton lysis buffer (1% Triton X-100, 50 mM Tris pH 8.0, 150 mM NaCl, 150 μg/ml PMSF). This, and all subsequent preparation steps, were performed at 4°C. Soluble extracts were pre-incubated for 30 min with 5 μl Protein-A resin slurry (Millipore, Temecula, CA) to remove non-specific binding proteins. Supernatants were collected and incubated for 2 hr with 10 μl STrEP-Tactin resin (IBA-Lifesciences, Göttingen, Germany). The resins were washed three times with 500 μl washing buffer (0.1% Triton-X100, 50 mM Tris, 150 mM NaCl, pH 8.0), resuspended in 35 μl SDS-PAGE loading buffer (2% SDS, 10% glycerol, 2% 2-mercaptoethanol (BME), 0.002% bromophenol blue and 62.5 mM Tris, pH 6.8), and boiled to release the bound proteins. 12 μl samples of each solution were electrophoresed (10% SDS-PAGE) and proteins were visualized by staining with Coomassie brilliant blue.

This procedure was repeated in three independent experiments, and in each case the protein band corresponding to AMOT p130 was visible in the Coomassie-stained gel ([Figure 1B](#fig1){ref-type="fig"}). This band was excised (and the equivalent region from the control lane was also excised in one of the repetitions), de-stained in 50% methanol with 50 mM ammonium bicarbonate (2 × 1 ml, 1 hr, 23°C, gentle vortexing), re-hydrated in 50 mM ammonium bicarbonate (1 ml, 30 min, 23°C), and cut into several pieces. Each piece was dehydrated in acetonitrile (1 ml, 30 min, 23°C, gentle shaking), and the excess acetonitrile was removed. Proteins were in-gel digested using 10--20 μl sequence-grade modified trypsin (Promega, Madison, WI, 20 ng/μl) in 50 mM ammonium bicarbonate (16 hr, 37°C), and the reaction was quenched by the addition of 20 μl 1% formic acid. The solution was removed and the gel washed twice with 50% acetonitrile in 1% formic acid (20 μl, 20 min, 37°C, with sonication) and once with 100% acetonitrile (20 min, 37°C, with sonication). The wash solutions were combined, dried, and reconstituted in 100 μl 5% acetonitrile with 0.1% formic acid for LC/MS/MS analysis.

Peptides were analyzed using a nano-LC/MS/MS system comprising a nano-LC pump (2D-ultra, Eksigent) and an LTQ-FT mass spectrometer (ThermoElectron Corporation, San Jose, CA), equipped with a nanospray ion source (ThermoElectron Corporation). 5--20 fmoles of each tryptic digest were injected onto a homemade C18 nanobore LC column (C18 \[Atlantis, Waters Corporation, Milford, MA\]); 3 μm particle; column (75 μm ID × 100 mm length), and eluted using a linear gradient of 5--70% solvent B in 78 min (solvent B: 80% acetonitrile with 0.1% formic acid; solvent A: 5% acetonitrile with 0.1% formic acid, 350 nl/min). The LTQ-FT mass spectrometer was operated in the data-dependent acquisition mode (Xcalibur 1.4 software) with the 10 most intense peaks in each FT primary scan determined on-the-fly and trapped for MS/MS analysis and CID peptide fragmentation/sequencing in the LTQ linear ion trap. Spectra in the FT-ICR were acquired from *m*/*z* 350 to 1400 at 50,000 resolution (∼2 ppm mass accuracy) with the following LTQ linear ion trap parameters: precursor activation time 30 ms and activation *Q* at 0.25; collision energy at 35%; dynamic exclusion width at 0.1 Da--2.1 Da, with one repeat count and 10 s duration.

Raw LTQ FT MS data files were converted to peak lists with BioworksBrowser 3.2 software (ThermoElectron Corporation) using the following processing parameters: precursor mass 351--5500 Da; grouping enabled, 5 intermediate MS/MS scans; precursor mass tolerance 5 ppm, minimum ion count in MS/MS = 15, and minimum group count = 1. Resulting DTA files were merged, and searched to identify peptides/proteins against NCBInr using the MASCOT search engine (Matrix Science Ltd.; version 2.2.1, Boston, MA). Searches were done with tryptic specificity, allowing two missed cleavages, or 'non-specific cleavage' and a mass error tolerance of 5 ppm in MS spectra (i.e., FT-ICR data) and 0.5 Da for MS/MS ions (i.e., LTQ linear ion trap). Identified peptides were accepted when the MASCOT ion score value exceeded 20. In all three repetitions, at least two peptides corresponding to AMOT p130 were identified in the tryptic digest, and the maximal coverage was 33% (see [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

Immunoprecipitations {#s4-3}
--------------------

To assay OSF-NEDD4L protein binding to endogenous AMOT p130 ([Figure 1C](#fig1){ref-type="fig"}), 293T cells (2 × 10^6^ cells per 10 cm plate) were transfected using Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA) with either 3.5 μg of an empty pCAG-OSF expression vector (control) or with pCAG-OSF vectors that expressed the designated OSF-NEDD4L proteins, using 3.5 μg of expression constructs for wild type NEDD4L or NEDD4L~ΔWW~, or 2 μg each of expression constructs for NEDD4L~C942A~ or NEDD4L~ΔWW/C942A~. In this case, and in all other experiments, empty vector was added to keep total DNA levels constant (i.e., 1.5 μg empty pCAG-OSF vector in the case of NEDD4L~C942A~ or NEDD4L~ΔWW/C942A~). 48 hr post transfection, cells were washed in PBS buffer and lysed (25 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% CHAPS, pH 7.5, 10 min, 4°C). Soluble lysates were collected by centrifugation (5000×*g*, 5 min, 4°C) and incubated with 50 μl STrEP-Tactin resin (IBA-Lifesciences, Göttingen, Germany, 3 hr, 4°C) equilibrated with lysis buffer. The resin was washed (25 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% CHAPS, pH 7.5, 3 × 1 ml), resuspended in 50 μl 2× SDS-PAGE loading buffer, boiled, and the released proteins were analyzed by SDS-PAGE and western blotting. Separated proteins were transferred to PVDF membranes, blocked with 5% non-fat dry milk for 45 min at RT, and incubated overnight at 4°C with primary antibodies (see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Secondary antibodies were anti-rabbit IgG or anti-mouse IgG conjugated to IRdye800 or IRdye700, respectively (1:10,000 and 1:20,000 respectively, Rockland Immunochemicals Inc., Gilbertsville, PA). All western blots were visualized using an Odyssey scanner (Li-Cor Biosciences, Lincoln, NB).

To assay OSF-NEDD4L protein binding to exogenous HA-AMOT p130 proteins ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), 293T cells (2 × 10^6^ cells per 10 cm plate) were co-transfected using Lipofectamine 2000 (Invitrogen/Life Technologies) with 3.5 μg of a pCAG-OSF vector expressing wild type OSF-NEDD4L and 3.5 μg of an empty pCAG vector (control), or pcDNA vectors expressing HA-AMOT p130 or HA-AMOT p130~ΔPPXY~. Thereafter, the co-immunoprecipitation protocol was identical to the one described above.

Bacterial protein expression and purification {#s4-4}
---------------------------------------------

Proteins were expressed in the Rosetta-pLysS bacterial strain grown in auto-induction media ZYP-5052 ([@bib47]).

### NEDD4L protein purification {#s4-4-1}

*E. coli* expressing GST-NEDD4L proteins (2 l) were harvested, resuspended in 80 ml lysis buffer (50 mM Tris, 150 mM NaCl, 5% glycerol, 2 mM MgCl~2~, 1 mM TCEP, 0.5% NP-40, 0.5 mM EDTA, pH 8.0) supplemented with the protease inhibitors PMSF (20 μg/ml), pepstatin (0.4 μg/ml), leupetin (0.8 μg/ml), and aprotinin (1.6 μg/ml). This and all subsequent steps were performed at 4°C. Lysate viscosity was reduced by addition of DNase (12.5 μg/ml, Roche, Basel, Switzerland). The lysate was clarified by centrifugation at 39,000×*g* for 45 min, and loaded onto 10 ml glutathione-superose resin (GE Healthcare Bio-Sciences, Pittsburgh, PA). The resin was washed with high-salt wash buffer (20 mM Tris, 1 M LiCl, 0.01% NP-40, 1 mM TCEP, 0.5 mM EDTA, 5% glycerol, pH 8.0) followed by low-salt wash buffer (20 mM Tris, 150 mM NaCl, 1 mM TCEP, 0.5 mM EDTA, 5% glycerol, pH 8.0) prior to elution (50 mM Tris, 150 mM NaCl, 5% glycerol, 1 mM TCEP, 0.5 mM EDTA, 20 mM reduced glutathione pH 8.0). PreScission protease (4 nmol protease/120 nmol purified protein, GE Healthcare Bio-Sciences) was added to remove the GST affinity tag and the sample was dialyzed overnight against the same buffer without glutathione. The cleaved protein was further purified on a Q-column (10 HiTrap HP-Q, GE Healthcare Bio-Sciences) equilibrated in buffer A (20 mM Tris, 50 mM NaCl, 5% glycerol, 1 mM TCEP, 0.5 mM EDTA, pH 8.0), and eluted with a linear gradient to buffer B (Buffer A, but with 1 M NaCl). NEDD4L-containing fractions were pooled and dialyzed against storage buffer (20 mM Tris, 150 mM NaCl, 20% glycerol, 1 mM TCEP, pH 8.0) and stored at −80°C. Typical yields were 60 nmol/l culture, and the protein identities were confirmed by electrospray mass spectrometry (NEDD4L: MW~calc~ = 98,472 g/mol, MW~exp~ = 98,474 g/mol; NEDD4L~ΔWW~: MW~calc~ = 98,012 g/mol, MW~exp~ = 98,014 g/mol).

### Gag~Δp6~ protein purification {#s4-4-2}

*E. coli* expressing HIV-1~HXB2~ Gag~Δp6~-GST (4 l) were harvested and resuspended in 150 ml of lysis buffer (50 mM HEPES, 500 mM NaCl, 5% glycerol, 2 mM MgCl~2~, 10 mM BME, 0.1% NP-40, 10 μM ZnCl~2~, pH 7.5) supplemented with protease inhibitors (PMSF, pepstatin, leupetin, and aprotinin). This and all subsequent steps were performed at 4°C. Lysate viscosity was reduced by addition of DNase (Roche) and the lysate was clarified by centrifugation (39,000×*g*, 45 min). Nucleic acids were removed by adding polyethylenamine (PEI at pH 8.0) to a final concentration of 1% (wt/vol), followed by centrifugation (27,000×*g*, 20 min). The fusion protein was precipitated by addition of 0.35 equivalents of saturated ammonium sulfate (to 26% saturation). The resulting pellets were resuspended in 80 ml of GST Loading Buffer (50 mM HEPES, 500 mM NaCl, 5% glycerol, 10 mM BME, 0.01% NP-40 and 10 μM ZnCl~2~, pH 7.5), and loaded onto 5 ml of glutathione-sepharose resin (GE Healthcare Bio-Sciences). The resin was washed with GST loading buffer, and the protein was cleaved overnight on-column by incubation in 80 ml cleavage buffer (50 mM Tris, 500 mM NaCl, 5% glycerol, 10 mM BME, and 10 μM ZnCl~2~, pH 7.5) supplemented with 0.5 mg PreScission protease (GE Healthcare Bio-Sciences). The flowthrough containing the cleaved protein was diluted to lower the salt concentration to 200 mM, and loaded onto an SP-column equilibrated in buffer A (50 mM Tris, 50 mM NaCl, 5% glycerol, 10 mM BME, 10 μM ZnCl~2~, pH 7.5). Gag~∆p6~ was eluted with a linear gradient to buffer B (buffer A, but with 1 M NaCl). Protein-containing fractions were pooled and dialyzed against storage buffer (20 mM Tris, 500 mM NaCl, 20% glycerol, 10 mM BME, 10 μM ZnCl~2~, pH 7.5) and stored at −80°C. Typical yields were 75 nmol/l, and the protein identity was confirmed by electrospray mass spectrometry (MW~calc,\ −Met1~ = 50,762 g/mol, MW~exp~ = 50,758 g/mol).

Streptactin pull-downs of Gag~Δp6~ and NEDD4L with OSF-AMOT {#s4-5}
-----------------------------------------------------------

For the experiments described in [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, SF9 cells (2 l) were infected at an MOI of 5 with Bac-to-Bac baculoviruses expressing OSF-tagged GFP (control), AMOT p130, AMOTL1 or AMOTL2. Pellets from 200 ml of culture were lysed in 10 ml of lysis buffer (1% NP-40, 150 mM NaCl, 20 mM Tris pH 8.0, 0.5 mM EDTA supplemented with protease inhibitors). All steps were performed at 4°C. Supernatants were collected by centrifugation for 30 min at 13,000 RPM in a microcentrifuge and 0.5 ml of each lysate was incubated with 30 μl of a slurry of STrEP-Tactin resin (1 hr). Resins were washed with high salt wash buffer (20 mM Tris, 1 M LiCl, 0.5 mM EDTA, 0.1% NP-40, pH 8.0), followed by low salt buffer (20 mM Tris, 150 mM NaCl, 0.5 mM EDTA, 0.1% NP-40, pH 8.0). For NEDD4L binding experiments, the OSF-GFP or OSF-AMOT-bound resins were washed with binding buffer (150 mM NaCl, 50 mM Tris, 1 mM TCEP, 10 μM ZnCl~2~, 0.1% NP-40, pH 7.5). Pure recombinant NEDD4L or NEDD4L~ΔWW~ proteins (0.5 μM in 500 μl binding buffer) were pre-incubated with washed resins for 1 hr, and then incubated for 1 hr with GFP- or AMOT-bound resins. Resins were washed three times with 250 μl binding buffer, resuspended in 30 μl SDS-PAGE loading buffer, boiled, separated by SDS-PAGE, and visualized by Coomassie staining or by Western blotting (with 1 μl samples used for Coomassie staining, and 1 μl samples of a 50-fold dilution used for Western blotting).

For Gag~Δp6~ binding experiments, the OSF-GFP (control)- or OSF-AMOT-bound resins were washed with binding buffer. Pure recombinant HIV-1 Gag~Δp6~ (1 μM) in 500 μl binding buffer was incubated with the washed resins for 1 hr. Resins were washed with binding buffer, and processed as described above.

NEDD4L and AMOT co-overexpression experiments {#s4-6}
---------------------------------------------

NEDD4L and AMOT protein family co-overexpression experiments shown in [Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"} were performed following the protocol: 293T cells (4 × 10^5^ cells/well in a 6-well plate) were co-transfected (Lipofectamine, 2000; Invitrogen/Life Technologies) with 1 μg of an R9-based expression vector for the NL4-3 strain of HIV-1~ΔPTAP,\ ΔYP~ ([@bib48]), 0.5 μg of pCI-FLAG NEDD4L or NEDD4L~ΔWW~ ([@bib8]) or pCI-FLAG empty vector in combination with either 0.5 μg of pCMV AMOT p80 ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) or 1 μg pcDNA3 HA-AMOT p130 ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) or 0, 0.25, 0.5, 0.75, 1, 1.25 or 1.5 μg pcDNA3 HA-AMOT p130, ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) or 1 μg pcDNA3 HA AMOTL1 or 1 μg pcDNA3 HA AMOTL2 ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). 48 hr post-transfection, media was harvested for titer measurements and virus purification, and cells were washed off the plate in PBS.

Viral titers were assayed in HeLa-TZM indicator cells using a β-galactosidase assay, and following the manufacturer\'s instructions (Promega, Madison, WI). Briefly, HeLa-TZM cells (5000 cells per well, 96-well plate) were infected with four different dilutions of virus-containing culture media, harvested after 48 hr, washed once (PBS, 4°C), and lysed in 25 mM Tris phosphate (pH 7.8), 2 mM DTT, 2 mM 1,2-diaminocyclohexane N,N,N′,N′-tetraacetic acid (DCTA), 10% glycerol and 1% Triton X-100 (10 min, 23°C). Cell lysates were incubated in 200 mM sodium phosphate buffer (pH 7.3), 2 mM MgCl~2~, 100 mM BME and 1.33 mg/ml ortho-Nitrophenyl-β-galactoside for 60 min at 37°C. Reactions were terminated by addition of 200 μl 1 M Tris base and absorbance at 420 nm was read in a plate reader.

For western blot analyses, virions were pelleted by centrifugation through a 20% sucrose cushion (90 min, 15,000×*g*, 4°C) and resuspended in SDS-PAGE loading buffer. Cells were washed in PBS, lysed in RIPA buffer (10 mM Tris, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, pH 8.0) supplemented with protease inhibitors (cOmplete, Roche) (10 min, 4°C), and the insoluble material was removed by centrifugation (10 min, 15,000×*g*, 4°C). Primary antibodies and dilutions used for western blots are given in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

AMOT siRNA depletion and re-expression experiments {#s4-7}
--------------------------------------------------

Depletion/re-expression experiments ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}, [Figure 7](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}) were performed following the protocol: t = 0: 293T cells (2.5 × 10^5^ cells/well, 6-well plate) were transfected with 10 nM siRNA using 7.5 μl Lipofectamine RNAiMax (Invitrogen/Life Technologies); t = 24 hr: media changed and second siRNA co-transfection with 10 nM siRNA and 0.5 μg wild type HIV-1 R9 expression vector or 1 μg HIV-1~ΔPTAP,\ ΔYPXL~ expression vector and 0.5 μg of pCI-FLAG NEDD4L (10 μl Lipofectamine, 2000; Invitrogen/Life Technologies); t = 72 hr: media and cells harvested for titer measurements and western blot analyses as described above. For the rescue experiments, siRNA-resistant expression constructs expressing AMOT p80, AMOT p130, AMOT p130~ΔPPXY~, AMOTL1 or AMOTL2 were co-transfected at t = 24 hr.

AMOT expression and effects on HIV-1 release from HeLa and Jurkat T cells {#s4-8}
-------------------------------------------------------------------------

AMOT mRNA is expressed in 293T cells and in white blood cells and lymphoid tissues, but cannot be detected in HeLa cells ([@bib35]). Western blots were performed to compare AMOT protein expression levels in 293T vs HeLa cells ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). 293T (2 x 10^6^ cells/10 cm plate) and HeLa M (1.2 x 10^6^ cells/10 cm plate) cells were seeded, harvested 72 hr later by trypsin treatment, washed twice in PBS, counted, lysed in RIPA buffer (1.2 × 10^5^ cells/μl) for 15 min at 4°C, clarified by centrifugation (15 min, 15,000×*g*, 4°C) and diluted 1:1 with 2× SDS loading buffer. 2.5, 5, 10 and 20 μl of each cell lysate mixture was loaded on a 4--15% gradient gel and AMOT proteins were detected by western blotting.

Experiments to test whether AMOT overexpression can stimulate HIV-1 release from HeLa cells ([Figure 6A](#fig6){ref-type="fig"}) were performed as follows: HeLa M cells (2.5 × 10^5^ cells/well in a 6-well plate) were co-transfected with 0.5 μg of wild-type R9 HIV-1 and 0.5, 1, 2 or 4 μg of pcDNA3-HA AMOT p130 expression vectors. Cells and viruses were harvested 48 hr post-transfection.

To test whether AMOT could stimulate virus release from physiologically relevant T cells, AMOT was overexpressed in Jurkat T cells as follows: t = 0, cells were harvested, washed in PBS and resuspended in Neon resuspension buffer R (Invitrogen/Life Technologies). 5 × 10^6^ cells were combined with 3 μg of the wild type R9 HIV-1 expression vector and 0, 5 or 10 μg of pcDNA3-HA AMOT p130 or AMOT p130~ΔPPXY~ expression vectors. Cells were then electroporated in a 100 µl tip with the Neon Transfection System using three 10 ms pulses of 1325 V. Following electroporation, each sample was immediately transferred to a 10 cm plate containing 10 ml pre-warmed RPMI (supplemented with 10% FBS and 2 mM glutamine). t = 96 hr: media and cells were harvested.

Protocols for analyzing protein expression and viral titers were identical to those described for 293T cells experiments.

Scanning electron microscopy (SEM) {#s4-9}
----------------------------------

293T cells (2.5 × 10^5^ cells/well, 6-well plate) were seeded onto glass cover slips (24 hr prior transfection) and co-transfected with the designated siRNAs and the R9 HIV-1 expression construct as described above. 48 hr post-transfection, the media was removed and cells were fixed in 1 ml fixation buffer (2.5% glutaraldehyde/1% paraformaldehyde in sodium cacodylate buffer; 50 mM sodium cacodylate, 18 mM sucrose, 2 mM CaCl~2~, pH 7.4, 10 min). This and all subsequent steps were performed at 23°C. Fixed cells were washed three times in sodium cacodylate buffer (5 min), and stained with 2% OsO~4~ for 1 hr. Each sample was then dehydrated in a graded ethanol series, dried in HDMS (hexamethyldisilazane), and sputter coated with platinum. SEM images were collected on a FEI Quanta 600 FEG scanning electron microscope at a beam energy of 10 kV, a spot size of three, and magnifications of 10,000, 30,000 or 65,000 X.

Transmission electron microscopy (TEM) {#s4-10}
--------------------------------------

293T cells (2.5 × 10^5^ cells/well, 6-well plate) were co-transfected with the designated siRNAs and the R9 HIV-1 expression construct as described above. 48 hr post-transfection, the media was removed and cells were fixed in 1 ml fixation buffer (2.5% glutaraldehyde/1% paraformaldehyde in sodium cacodylate buffer \[50 mM sodium cacodylate, 18 mM sucrose, 2 mM CaCl~2~, pH 7.4, 10 min\]). This and all subsequent steps were performed at 23°C. Fixed cells were harvested, washed three times in sodium cacodylate buffer (5 min), and stained with 2% OsO~4~ for 1 hr. The pellet was rinsed once in sodium cacodylate buffer and twice in water (5 min), followed by incubation in 100 μl of a 4% uranyl acetate solution (30 min). Stained cells were dehydrated in a graded ethanol series followed by acetone, and embedded in epoxy resin EMBed-812 (Electron Microscopy Sciences, Hatfield, PA). Thin sections (80--100 nm) were cut, post-stained with saturated uranyl acetate (20 min), rinsed with water, dried, stained with Reynolds\' lead citrate (10 min) and dried again. TEM images were collected on a Hitachi H-7100 transmission electron microscope at an accelerating voltage of 75 kV, equipped with a Gatan Orius sc1000 camera.

Imaged virions were scored as 'mature' if they lacked an observable cellular tether and a condensed core was evident, as 'immature' if they were untethered but lacked a condensed core, and as 'budding' if a Gag layer was clearly evident and the nascent virion was assembling or was clearly tethered to the cell. The degree of assembly was assessed by rendering a (hypothetical) spherical particle and measuring the arc angle of the nascent Gag layer. To image 500 virions budding from wild type cells, it was necessary to screen about eight-times as many thin slices of wild type control cells (∼2500 cells) vs TSG101- or AMOT-depleted cells (275 and 300, respesctively).
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It was shown in the manuscript that AMOT proteins can simultaneously interact with NEDD4l E3 ligase and HIV-Gag protein and thereby facilitate budding of newly formed HIV virions. The hypothesis is that Nedd4L could be indirectly recruited to Gag via these AMOT proteins. This is an attractive hypothesis because it would explain earlier findings that "crippled" HIV-1 Gag proteins lacking PTAP and YPXL late domains can be induced to function for budding by overexpression of Nedd4L, despite the lack of PPxY motifs in Gag, or any other obvious way to recruit Nedd4L to Gag protein. Functional budding assays demonstrate that AMOT and Nedd4L cooperate to stimulate budding of the crippled HIV-1 Gag, and that AMOT depletion reduces budding of wt HIV-1. Budding could be restored through re-expression of AMOT, AMOTL1, or AMOTL2 from plasmids. An extensive EM analysis of budding HIV-1 particles upon AMOT depletion was performed. AMOT depletion leads to a block in particle formation that is earlier (half-moon stage) than the one caused by Tsg101 depletion (lollipop stage).

The quality of the data presented here is high and the reviewers were enthusiastic about the overall importance of the presented data. However, the reviewers agreed that the following issues need to be addressed before the manuscript can be considered for publication in *eLife*:

More information on the physiological significance AMOT-Gag interactions should be provided. For example, AMOT does not exist in many cell types and most of the studies required a Gag missing the late domains. Maybe AMOT only plays a role in Gag budding missing the late domains -- but never plays a role in normal physiological assembly. What is the importance of AMOT for virus budding in different cell types, and what is the status of HIV budding in HeLa cells that are naturally deficient for AMOT. Could AMOT be acting on something else which, in turn, facilitates assembly? Does AMOT play a role normally in assembly of HIV-1, or only when they have late domains missing? Is Amot functioning at the sites of assembly? What is the relative timing of AMOT and ESCRTs. What is the evidence that AMOT is a pre-requisite for recruitment of ESCRTs rather than being a parallel process? When AMOT is depleted in the HEK293 cells and the half-moon shapes are formed, is ESCRT recruited to these half-moon shapes?

The interaction of NEDD4 and AMOT has been already shown previously, where NEDD4 ubiquitination of AMOT leads to its degradation via UPS. Authors as well demonstrate in one figure that overexpression of NEDD4 leads to decrease in total level of AMOT. However, in contradiction to this, they used NEDD4 overexpression in all experiments. One would expect that presence of AMOT negatively affects HIV release, by blocking access of NEDD4 and that overexpression of NEDD4 hence neutralizes overexpression of AMOT, by targeting it for the UPS degradation. How is than degradation of AMOT regulation during the HIV budding? Does presence of Gag neutralizes NEDD4 mediated degradation of AMOT? Could authors test this in their assays, and correlate the levels of AMOT in setting where NEDD4 is not overexpressed, and HIV budding is followed? In such setting both wt and dPTAP Gag should be tested, and compared.

Does increased concentration of HIVGag in the binding assays can outcompete NEDD4 binding? Further, the domain/motif in AMOT that binds to HIVGag should be identified, and this mutant should be tested in all budding/infection assays.

Minor comments:

Reviewer \#1:

1\) Does HIVGag negatively influences NEDD4 mediated ubiqutination of AMOT? Could authors test this in cells or in vitro. In case is so, does that support the fact that AMOT is stabilized upon HIV infection and only than is not degraded but facilitates ubiquitination of Gag?

2\) AMOT contains BAR domain, however authors do not have an attempt to test the requirement of BAR domain in proposed process, despite the fact that BAR domains are known to be able to remodel/recognize membrane curvature. [Figure 3](#fig3){ref-type="fig"} shows clearly that overexpression of AMOT leads to formation of large aggregate-like structures that are rather artefacts of overexpression than functional co-localization of AMOT with NEDD4. Authors should look closely on localization of endogenous AMOT in cells, and demonstrate its co-localization with HIV-Gag. Picture of Hiv-Gag localization should be provided in both wt and AMOT deficient cells as well.

3\) [Figure 9](#fig9){ref-type="fig"} should contain pictures of wt and rescued cells as well, and not only TSG101 and AMOT depleted cells.

4\) It is not clear how does presence of AMOT affect the assembly of ESCRT machinery via influencing NEDD4. Considering that AMOT deficient cells are not even able to form the buds one can speculate that AMOT might be important for the actin cytoskeleton regulation and membrane curvature around the bud. Could authors provide TIRF images, showing recruitment of AMOT to HIV buds, and subsequent recruitment of ESCRT components, as they propose in the Ddiscussion. Currently there is no evidence that AMOT acts upstream of ESCRT beside the fact that AMOT binds NEDD4. Does ESCRT get recruited at all in case of AMOT deficient cells? Does AMOT precede recruitment of ESCRT when budding events are followed by TIRF?

5\) If AMOT is required for NEDD4 recruitment and presumably subsequent ubiquitination, could authors also provide western blots showing levels of HIVGag ubiquitination in case of AMOT depletion or overproduction, in setting where only endogenous NEDD4 is present?

6\) [Figure 8A](#fig8){ref-type="fig"}, right panel: more representative blot should be provided, since this one is not convincing at all. MA protein is not detected at all in viral particles, and the differences in CA level are almost not visible, going against the whole proposed mechanism that AMOT is able to surpass the lack of PTAP in crippled HIVGag.

7\) Would be beneficial for the reader to have domain/motif comparison of all AMOTs (including AMOTL1 and AMOTL2) in [Figure 1](#fig1){ref-type="fig"}, or somewhere else in the figures. Based on which characteristic are those proteins redundant in terms of HIVGag budding.

Reviewer \#2:

1\) The binding experiments for the Nedd4L-AMOT interaction are carried out using a variety of constructs to localize binding determinants. Less so for the experiments characterizing the new interaction between Gag and AMOT. Have the authors tested whether AMOT p80 binds to Gag? If so, it would be useful to mention it, for example, on the third paragraph of the subsection "AMOT p130 is required for NEDD4L stimulation of HIV-1 budding", in the Results section, referring to Figure 5--figure supplement 2: "Hence, Nedd4L stimulation... requires the presence of an AMOT p130 protein that can bind NEDD4L...". The authors seem to attribute the lack of Nedd4L stimulation solely to lack of binding between p80 and NEDD4L. This is a case where it would be helpful to know if p80 binds to HIV-1 Gag. If not, it would mean that there are multiple defects in p80 that prevent it from functioning for the stimulation of Gag budding.

2\) The sentence in the fourth paragraph of the subsection "AMOT p130 is required for NEDD4L stimulation of HIV-1 budding", in the Results section, referring to [Figure 5](#fig5){ref-type="fig"}: "However, this stimulation was completely abrogated when endogenous AMOT proteins were depleted". This is a key experiment in the paper. It is clear that full stimulation in these experiments requires both AMOT (endogenously expressed) and Nedd4L (from plasmid), and I believe that is the key point being made here. However, the statement that stimulation was completely abrogated when AMOTs were depleted may be a bit misleading. It implies that in the absence of AMOT, Nedd4L expression has no effect. But it does (compare lanes 2 and 4 of [Figure 5](#fig5){ref-type="fig"}). Please rephrase. This result is, perhaps, to be expected given that AMOTL1 and AMOTL2 are still present in these cells.

3\) The sentence in the third paragraph of the subsection "AMOT p130 is required for NEDD4L stimulation 242 of HIV-1 budding", in the Results section, referring to Figure 5--figure supplement 1: "the degree of rescue correlated positively with AMOT p130 re-expression levels...". Certainly this appears to be true when looking at the infectivity assays in Figure 5--figure supplement 1, but such definitive language is not supported as well by the Gag budding experiment shown in the western blot of that figure.

4\) The authors may want to point out that the partial rescue by AMOTL1 and AMOTL2 seen in [Figure 8](#fig8){ref-type="fig"} could be related to differences in expression levels of the 3 AMOT proteins in the cells, which would be consistent with the dose dependence effect observed in [Figure 7](#fig7){ref-type="fig"}.

Reviewer \#3:

It would help in the text to indicate which cells were used when (e.g., for the EM the cell type is not mentioned in the text nor the figure legend. It would help to have more information on the constructs used. The text says that HIV-1 was expressed using R9 wildtype. From looking back at a previous article that is referenced (Chung, 2008), it appears to be a pro-viral plasmid. However, that article does not have the R9 listed in its supplemental table of plasmids and references back to a paper from the year before (Fisher, 2007) that does not have the R9 listed. For [Figure 4 and 5](#fig4 fig5){ref-type="fig"}, there are panels called "virus". Would it be better to call these "supernatant"? There are virions in both the cells and the supernatent. Why is there such a dramatic effect on infectivity when the effect on viral protein in the supernatant is not as pronounced?

It is claimed in the first paragraph of the subsection headed "AMOT binds directly to NEDD4L and to HIV-1 Gag2 in the Results section that NEDD4L binds AMOTp130 with at least 1:1 stoichiometry. How was this conclusion reached from the gel?

10.7554/eLife.03778.023

Author response

\[Editors' note: the authors asked for clarification about the revision requirements prior to resubmission.\]

We have first listed your final set of requirements and our responses to them. In addition, we have also addressed many of the comments made in the original reviews, and we have also described those cases.

*Test the role of AMOT directly in physiologically relevant cells. If experiments with the T-cells are difficult, use macrophages instead*.

As the reviewers pointed out, our original manuscript did not test the role of AMOT in cells that are physiologically for HIV-1 infection. To address this shortcoming, we have now tested how altering AMOT p130 levels affects the release of infectious HIV-1 particles from Jurkat T cells. These experiments were performed by comparing the effects of overexpressing either wild type AMOT p130 or an inactive AMOT p130 mutant with point mutations in the three NEDD4-binding "PPXY" motifs (AMOT p130~ΔPPXY~). As shown in the new [Figure 6B](#fig6){ref-type="fig"}, we find that overexpression of wild type AMOT p130 strongly stimulates HIV release and infectivity in a dose-dependent fashion, with maximal stimulations of 16-fold (virion release) and 7-fold (viral infectivity) vs. a transfected vector control. In contrast, overexpression of AMOT p130~ΔPPXY~ reproducibly reduced HIV-1 release and infectivity, presumably by dominantly inhibiting the functions of endogenous AMOT p130 proteins. We have confirmed that the levels of HIV-1 protein expression are comparable in all cases (not shown). AMOT expression levels in Jurkat T cells are beneath our detection limits, but we feel confident in concluding that AMOT stimulates HIV-1 release in this setting because the experiment is well controlled by the use of an inactive point mutant AMOT p130 construct, because the effects are dose dependent, and because we repeated the experiment three times with similar results.

In the process of investigating how best to perform this experiment, we also noticed that one of published the "global" siRNA screens for HIV cofactors was performed in Jurkat T cells ([@bib57]). Gratifyingly, the data from that screen also indicate that AMOT is important for HIV-1 replication in Jurkat T cells because an shRNA that targeted AMOT protected Jurkat cells against the cytotoxicity that occurs upon HIV infection (although the functional role of AMOT was not pursued further). Thus, there are now two independent lines of evidence that AMOT p130 is important for HIV-1 replication in Jurkat T cells (and we have, of course, now referenced [@bib57]).

*Explain why Tsg101 knockdown is so much more effective than AMOT in HIV infectivity*.

This is also a good point. We hypothesized that the strong, but incomplete effects that we were seeing might reflect incomplete silencing of endogenous AMOT p130. We therefore repeated the experiment with a new, freshly repurified batch of siRNA. Importantly, this new AMOT p130 siRNA depleted both AMOT p130 and p80 even more efficiently than our previous batch of siRNA (see new [Figure 5](#fig5){ref-type="fig"}, panel 3, lane 4). As shown in the new [Figure 5](#fig5){ref-type="fig"}, this siRNA treatment reduces viral titers by approximately 8-fold, and the inhibition of virion release is approaching the inhibition that we see for our best siRNA against TSG101 (right panels, compare lanes 3 and 4). We therefore conclude that most (or all) of the residual virus release and infectivity that we saw in previous experiments was due to incomplete silencing of AMOT p130 (and/or the residual presence of AMOT L1 and L2). These data indicate that AMOT p130 is (nearly) as important as TSG101 for HIV-1 release. Finally, we note that: 1) In addition to reducing viral budding, TSG101 depletion also reduces HIV-1 infectivity by inhibiting Gag processing and viral maturation, whereas AMOT depletion only appears to inhibit by blocking budding (see the data in [Figure 9](#fig9){ref-type="fig"} and the discussion below), and 2) the level of infectivity seen upon depletion of either AMOT p130 or TSG101 is significantly greater than the infectivity reduction seen upon depletion of the third known HIV budding factor, ALIX ([Figure 5](#fig5){ref-type="fig"}).

Please note that we have not gone back and repeated all of our siRNA rescue experiments with the new batch of siRNA because this would have required repeating a very large number of experiments and because the new experiment did not change our original conclusions.

*Test the effect of AMOT expression with HIV-1 R-9 in Hela cells*.

This experiment, i.e., examining the release of wild type HIV-1~NL4-3~ from HeLa cells (expressed from the R9 proviral expression vector), was already shown in [Figure 7](#fig7){ref-type="fig"} of the original paper (now [Figure 6A](#fig6){ref-type="fig"}). As we have discussed, the misunderstanding arose from an error that we made in mislabeling the HIV-1 construct in the figure caption (for which we apologize) and also from an apparent misunderstanding of the nomenclature that we used within the figure (and elsewhere). Viruses and proteins labeled "HIV-1" and "Gag" without any subscripts refer to the wild type virus and Gag protein, respectively. Viruses and Gag proteins that lack late domains are labeled with the subscripts "ΔPTAP, ΔYP". We apologize for the confusion, and note that AMOT expression strongly stimulates release of wild type HIV-1 in HeLa cells.

*More information on the physiological significance AMOT-Gag interactions should be provided*. *For example, AMOT does not exist in many cell types.*

Firstly, we note that AMOT is expressed in white blood cells and lymphoid tissues---the normal host cells for HIV-1 infection---and we have provided this information and relevant references in the manuscript. AMOT is not expressed in HeLa cells (but AMOTL2 is), and we show that exogenous expression of AMOT stimulates virus release from HeLa cells ([Figure 6A](#fig6){ref-type="fig"}). AMOT is expressed in Jurkat T cells (and this point is now made explicitly and referenced in the text, but AMOT nevertheless appears to be limiting because exogenous AMOT expression also stimulates HIV release from Jurkat T cells (new [Figure 6B](#fig6){ref-type="fig"}).

Reviewer \#1:

[*Figure 3*](#fig3){ref-type="fig"} *shows clearly that overexpression of AMOT leads to formation of large aggregate-like structures that are rather artefacts of overexpression than functional co-localization of AMOT with NEDD4*.

We agree (and had pointed that out ourselves), but the reviewer's point is well taken and we have therefore removed this figure from the manuscript and simply mentioned the co-localization as "data not shown". We think there is no doubt that AMOT p130 and NEDD4L bind one another in cells, and do so through interactions between the AMOT p130 PPXY motifs and the NEDD4L WW domains. We have shown this in several ways in our paper, including by co-IP ([Figure 2](#fig2){ref-type="fig"}). We have also referenced other relevant papers showing that motins bind NEDD4 family members.

[*Figure 9*](#fig9){ref-type="fig"} *should contain pictures of wt and rescued cells as well, and not only TSG101 and AMOT depleted cells*.

We, and others, have previously published EM images of thin-sectioned cells that show budding of wild type HIV-1 particles. Wild type virions bud efficiently, however, and it is therefore difficult to obtain images from single thin sections that contain numerous examples of budding wild type virions. To help address this limitation, we have turned to scanning electron microscopy (SEM). The advantage of SEM is that we can look at the entire surface of a cell and therefore capture many more budding events in a single image. We have now included such images for virions budding from control cells and from cells depleted of TSG101 and AMOT (new [Figure 8](#fig8){ref-type="fig"}). These images make it clear that there is an enormous difference between the efficiency of virus budding from wild type cells vs. cells that lack either TSG101 or AMOT.

*Would be beneficial for the reader to have domain/motif comparison of all AMOTs (including AMOTL1 and AMOTL2) in* [*Figure 1*](#fig1){ref-type="fig"}*, or somewhere else in the figures. Based on which characteristic are those proteins redundant in terms of HIVGag budding*.

We agree and have now included the requested domain comparison within the modified [Figure 1](#fig1){ref-type="fig"}.

Reviewer \#2:

*The binding experiments for the Nedd4L-AMOT interaction are carried out using a variety of constructs to localize binding determinants. Less so for the experiments characterizing the new interaction between Gag and AMOT. Have the authors tested whether AMOT p80 binds to Gag? If so, it would be useful to mention it, for example, on the third paragraph of the subection "AMOT p130 is required for NEDD4L stimulation of HIV-1 budding", in the Results section, referring to Figure 5--figure supplement 2: "Hence, Nedd4L stimulation... requires the presence of an AMOT p130 protein that can bind NEDD4L...". The authors seem to attribute the lack of Nedd4L stimulation solely to lack of binding between p80 and NEDD4L. This is a case where it would be helpful to know if p80 binds to HIV-1 Gag. If not, it would mean that there are multiple defects in p80 that prevent it from functioning for the stimulation of Gag budding*.

We have not tested AMOT p80 binding to Gag because the p80 isoform does not express well and we have therefore been unable to make pure recombinant AMOT p80. The reviewer is therefore correct that there may be multiple reasons that the p80 isoform does not support virus release. We believe, however, that we have shown that the lack of NEDD4L binding is sufficient to explain the lack of function of AMOT p80. The paragraph that the reviewer refers to also describes an experiment in which we show that an AMOT p130 protein with substitution mutations in the three PPXY motifs also fails to support HIV budding ([Figure 4](#fig4){ref-type="fig"}, AMOT p130~ΔPPXY~, right panels, compare lanes 6 and 5) and we therefore feel justified in concluding that NEDD4L stimulation requires the presence of an AMOT p130 protein that can bind NEDD4L.

*The sentence in the fourth paragraph of the subection "AMOT p130 is required for NEDD4L stimulation of HIV-1 budding", in the Results section, referring to* [*Figure 5*](#fig5){ref-type="fig"}*: "However, this stimulation was completely abrogated when endogenous AMOT proteins were depleted". This is a key experiment in the paper. It is clear that full stimulation in these experiments requires both AMOT (endogenously expressed) and Nedd4L (from plasmid), and I believe that is the key point being made here. However, the statement that stimulation was completely abrogated when AMOTs were depleted may be a bit misleading. It implies that in the absence of AMOT, Nedd4L expression has no effect. But it does (compare lanes 2 and 4 of* [*Figure 5*](#fig5){ref-type="fig"}*). Please rephrase. This result is, perhaps, to be expected given that AMOTL1 and AMOTL2 are still present in these cells*.

The reviewer makes a good point. We have rephrased the sentence to read: "However, virus release was reduced to the levels seen in untreated control cells when endogenous AMOT proteins were simultaneously depleted (compare lanes 2-4).

*The sentence in the third paragraph of the subsection "AMOT p130 is required for NEDD4L stimulation 242 of HIV-1 budding", in the Results section, referring to Figure 5--figure supplement 1: "the degree of rescue correlated positively with AMOT p130 re-expression levels...". Certainly this appears to be true when looking at the infectivity assays in Figure 5--figure supplement 1, but such definitive language is not supported as well by the Gag budding experiment shown in the western blot of that figure*.

We take the reviewer's point, and have modified the sentence as follows: "the degree of rescue generally correlated positively with AMOT p130 re-expression levels."

*The authors may want to point out that the partial rescue by AMOTL1 and AMOTL2 seen in* [*Figure 8*](#fig8){ref-type="fig"} *could be related to differences in expression levels of the 3 AMOT proteins in the cells, which would be consistent with the dose dependence effect observed in* [*Figure 7*](#fig7){ref-type="fig"}.

We agree, and have added the following sentence that addresses this point: "Neither AMOTL1 nor AMOTL2 was quite as effective as AMOT p130 in rescuing HIV-1 infectivity in this assay, possibly because these motins are intrinsically less active than AMOT p130 and/or because they were expressed at lower levels (left panel 2, compare lanes 3-5)."

Reviewer \#3:

*It would help in the text to indicate which cells were used when (e.g., for the EM the cell type is not mentioned in the text nor the figure legend*.

We have now defined the cell type used in every experiment.

*It would help to have more information on the constructs used. The text says that HIV-1 was expressed using R9 wildtype. From looking back at a previous article that is referenced (Chung, 2008), it appears to be a pro-viral plasmid. However, that article does not have the R9 listed in its supplemental table of plasmids and references back to a paper from the year before (Fisher, 2007) that does not have the R9 listed*.

The reviewer is correct that R9 is a wild type proviral HIV-1 construct. In the previous version of the manuscript, there were two references for the relevant sentence of the experimental methods. One ([@bib48]) referred to the first report of the R9 proviral plasmid, and the other ([@bib8]) referred to our previous report of the NEDD4L plasmids used in this study. We have now separated the two references within the sentence to remove any confusion.

*For* [*Figure 4 and 5*](#fig4 fig5){ref-type="fig"}*, there are panels called "virus". Would it be better to call these "supernatant"? There are virions in both the cells and the supernatent*.

We understand the point, but prefer to use the term "virus" to remain consistent with other papers in the field.

Why is there such a dramatic effect on infectivity when the effect on viral protein in the supernatant is not as pronounced?

This is a good question. We (and others) generally observe a correlation between virion release and infectivity measurements, but the correlation is not perfect. This is why we believe it is important to measure both release and infectivity. One cause of these discrepancies is that budding defects can also induce defects in viral maturation and in virion contents. This is well characterized in the case of TSG101 depletion, where defective Gag processing and viral maturation contribute to loss of infectivity, even when virions are released. This effect is evident in the control experiment shown in [Figure 9](#fig9){ref-type="fig"}. Another effect that we have documented for TSG101 is that the released virions have reduced levels of reverse transcriptase. We believe that this is because even when virus budding does occur it is slow, and the processed RT proteins "float away" during the prolonged budding step. We envision that a similar effect probably occurs when AMOT depletion slows virus release, though we have not tested this directly. The important point is that aberrant kinetics of virion release appears to reduce infectivity, whereas any virions that eventually escape the cell will contribute to the signal in the release assay. Thus, treatments that disrupt (or restore) wild type virus budding kinetics can have differential effects on virion release and infectivity.

It is claimed in the first paragraph of the subsection headed "AMOT binds directly to NEDD4L and to HIV-1 Gag2, in the Results section, that NEDD4L binds AMOTp130 with at least 1:1 stoichiometry. How was this conclusion reached from the gel?

NEDD4L is a smaller protein than OSF-AMOT p130, yet the intensities of the Coomassie-stained NEDD4L band are significantly darker than the intensities of the OSF-AMOT p130 bands in the pulled down complexes shown in [Figure 2B](#fig2){ref-type="fig"}, panel 1, lanes 9 and 10. Thus, there must be at least as many molecules of NEDD4L as AMOT p130 in the complexes.
